

Cenra Inc. and subsidiaries
Consolidated financial statements and Auditor's
Report
Q1 2026 and 2025
(Stock Code: 3716)

Addresses: No.23, Hsiang Yang Rd., Taipei City 100

TEL: (02) 2312-4200

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

Centra Inc. and subsidiaries

Q1 2026 and 2025 Consolidated Financial Report and Independent Auditor's Review

Report

Table of Contents

Item	Page
1. Cover	1
2. Table of Contents	2 ~ 3
3. Auditor's Report	4 ~ 5
4. Consolidated Balance Sheet	6 ~ 7
5. Consolidated comprehensive income statements	8 ~ 9
6. Consolidated statement of changes in equity	10
7. Consolidated cash flow statement	11 ~ 12
8. Notes to consolidated financial statement	13 ~ 64
(1) Company history	13
(2) Financial statements approval date and procedure	13
(3) Application of New Standards, Amendments and Interpretations	13 ~ 14
(4) Summary of significant accounting policies	14 ~ 16
(5) Critical accounting judgments, estimates and key sources of assumption uncertainty	16

Item	Page
(6) Summary of significant accounting titles	16 ~ 44
(7) Related party transactions	44 ~ 48
(8) Pledged assets	48
(9) Significant contingent liabilities and unrecognized contractual commitments	48 ~ 49
(10) Significant disaster loss	49
(11) Significant subsequent events	49
(12) Other	49 ~ 62
(13) Notes of disclosure	63
(14) Segment information	63 ~ 64

REPORT ON REVIEW OF FINANCIAL STATEMENTS TRANSLATED FROM CHINESE

To the Board of Directors and Stockholders of Cenra Inc.

Introduction

We have reviewed the accompanying consolidated balance sheets of Cenra Inc. and subsidiaries (the "Group") as at March 31, 2026 and 2025, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the three-month periods then ended, and notes to the consolidated financial statements, including a summary of material accounting policies. Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" that came into effect as endorsed by the Financial Supervisory Commission. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of review

Except as explained in the following paragraph, we conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for qualified conclusion

The financial statements of certain insignificant consolidated subsidiaries were not reviewed by independent auditors. Total assets of these subsidiaries amounted to \$528,893 and \$563,754, constituting 4.20% and 4.48% of the consolidated total assets as at March 31, 2026 and 2025, respectively, total liabilities amounted to \$369,992 and \$341,263, constituting 7.77% and 6.90% of the consolidated total liabilities as at March 31, 2026 and 2025, respectively, and the total comprehensive income amounted to \$(1,970) and \$(15,187), constituting (0.96%) and (11.18%) of the consolidated total comprehensive income for the three-month periods then ended, respectively.

Qualified conclusion

Except for the adjustments to the consolidated financial statements, if any, as might have been determined to be necessary had the financial statements of certain consolidated subsidiaries been reviewed by independent auditors as described in the Basis for qualified conclusion section above, based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as at March 31, 2026 and 2025, and of its consolidated financial performance and its consolidated cash flows for the three-month periods then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" that came into effect as endorsed by the Financial Supervisory Commission.

Cenra Inc. and subsidiaries
Consolidated Balance Sheet
March 31, 2026, December 31 and March 31, 2025

Unit: NTD thousand

Assets	Additional notes	March 31, 2026		December 31, 2025		March 31, 2025		
		Amount	%	Amount	%	Amount	%	
Current assets								
1100	Cash and cash equivalents	6 (1)	\$ 900,139	7	\$ 729,497	6	\$ 745,094	6
1136	Financial assets measured at the amortized cost-current	6 (5)	-	-	-	-	98,168	1
1150	Notes receivable-net	6 (2)	292,716	2	333,986	3	349,752	3
1160	Notes Receivable-Related Parties- net	7	115,301	1	116,929	1	67,890	1
1170	Notes accounts, net	6 (2)	1,498,043	12	1,466,325	12	1,493,588	12
1180	Account receivables-Related Parties- net	7	27,432	-	40,982	-	39,199	-
1197	Finance lease receivables, net	6 (9)	651	-	647	-	-	-
1200	Other receivables		12,430	-	16,476	-	21,350	-
1210	Other receivables - related parties	7	212,793	2	189,359	1	263,975	2
1220	Current income tax asset		43,852	1	43,854	-	44,149	-
130X	Inventory	6(3)	2,621,006	21	2,708,659	22	2,700,802	21
1470	Other current assets		138,738	1	111,483	1	79,035	1
11XX	Total current assets		<u>5,863,101</u>	<u>47</u>	<u>5,758,197</u>	<u>46</u>	<u>5,903,002</u>	<u>47</u>
Non-Current assets								
1517	The financial assets measured for the fair values through other comprehensive income-non-current	6 (4)	204,610	2	166,496	1	188,594	1
1535	Financial assets measured at the amortized cost-non-current	6 (5)	139,513	1	134,866	1	-	-
1550	Investment under the equity method	6 (6) and 7	1,467,344	12	1,428,849	12	1,522,483	12
1600	Property, plant, and equipment	6(7) and 8	3,922,294	31	3,952,523	32	4,039,735	32
1755	Right-of-use assets	6 (8)	359,382	3	369,122	3	368,348	3
1760	Net amount of investment oriented real estate	8	114,879	1	114,082	1	117,584	1
1780	Intangible assets		42,389	-	10,215	-	10,482	-
1840	Deferred income tax assets		192,043	1	211,676	2	213,800	2
194D	Long-term finance lease receivables, net	6 (9)	3,327	-	3,492	-	-	-
1990	Other non-current assets- Other	6(10) and 8	274,385	2	297,671	2	232,326	2
15XX	Total of Non-Current Assets		<u>6,720,166</u>	<u>53</u>	<u>6,688,992</u>	<u>54</u>	<u>6,693,352</u>	<u>53</u>
1XXX	Total assets		<u>\$ 12,583,267</u>	<u>100</u>	<u>\$ 12,447,189</u>	<u>100</u>	<u>\$ 12,596,354</u>	<u>100</u>

(Continued on next page)

Cenra Inc. and subsidiaries
Consolidated Balance Sheet
March 31, 2026, December 31 and March 31, 2025

Unit: NTD thousand

Liabilities and equity	Additional notes	March 31, 2026		December 31, 2025		March 31, 2025		
		Amount	%	Amount	%	Amount	%	
Current liabilities								
2100	Shot-term borrowings	6(11) and 8	\$ 2,057,785	16	\$ 2,007,743	16	\$ 1,777,184	14
2110	Short-term notes payable	6 (12)	410,000	3	380,000	3	507,000	4
2130	Contractual liability- current	6 (21)	68,640	1	39,937	-	36,664	-
2150	Notes payable		796	-	807	-	453	-
2170	Accounts payable	7	759,189	6	750,296	6	765,033	6
2200	Other payables	6 (13)	555,593	4	720,125	6	645,765	5
2230	Current Tax Liability		93,057	1	74,126	1	80,556	1
2280	Lease liabilities - current		55,031	1	54,789	-	49,860	-
2320	Current portion of long-term liabilities	6(14) and 8	-	-	-	-	25,200	-
2365	Refund liability – liquidity	6 (21)	21,846	-	58,706	1	69,112	1
2399	Other current liabilities- other		17,747	-	13,091	-	21,608	-
21XX	Total current liabilities		<u>4,039,684</u>	<u>32</u>	<u>4,099,620</u>	<u>33</u>	<u>3,978,435</u>	<u>31</u>
Non-current liabilities								
2540	Long-term borrowings	6(14) and 8	230,400	2	240,800	2	464,000	4
2570	Deferred tax liabilities		162,304	1	153,379	1	154,148	1
2580	Lease liabilities – non-current		292,909	3	302,766	3	298,207	2
2600	Other non-current liabilities	6 (8)	37,329	-	38,992	-	50,499	1
25XX	Total of non-current liabilities		<u>722,942</u>	<u>6</u>	<u>735,937</u>	<u>6</u>	<u>966,854</u>	<u>8</u>
2XXX	Total liabilities		<u>4,762,626</u>	<u>38</u>	<u>4,835,557</u>	<u>39</u>	<u>4,945,289</u>	<u>39</u>
Equity of the parent company								
	Capital stock	6 (17)						
3110	Common stock capital		1,497,656	12	1,497,656	12	1,490,405	12
	Capital surplus	6 (18)						
3200	Capital surplus		5,907,847	46	5,907,847	48	5,971,603	48
	Retained earnings	6 (19)						
3310	Legal reserve		11,362	-	11,362	-	-	-
3320	Special reserve		222,767	2	222,767	2	188,958	2
3350	Unappropriated Retained Earnings		445,538	4	252,494	2	169,637	1
	Other equity	6 (20)						
3400	Other equity		(154,972)	(1)	(173,841)	(2)	(143,186)	(1)
3500	Treasury stock	6 (17)	(146,631)	(1)	(146,631)	(1)	(66,405)	(1)
31XX	Equity attributable to owners of the parent Company		<u>7,783,567</u>	<u>62</u>	<u>7,571,654</u>	<u>61</u>	<u>7,611,012</u>	<u>61</u>
36XX	Non-controlling interest		<u>37,074</u>	<u>-</u>	<u>39,978</u>	<u>-</u>	<u>40,053</u>	<u>-</u>
3XXX	Total equity		<u>7,820,641</u>	<u>62</u>	<u>7,611,632</u>	<u>61</u>	<u>7,651,065</u>	<u>61</u>
	Significant contingent liabilities and unrecognized contractual commitments	9						
	Significant subsequent events	11						
3X2X	Total Liabilities and Equity		<u>\$ 12,583,267</u>	<u>100</u>	<u>\$ 12,447,189</u>	<u>100</u>	<u>\$ 12,596,354</u>	<u>100</u>

Please refer to the notes enclosed in the consolidated financial reports that are an integral part of the consolidated financial statements.

Chairman: Wang Ming-Ning Memorial Foundation Manager: Wang, Hou-Kai Accounting Supervisor: Hiang, Hsien-Chieh
Representative: Wang Hsien, I-Chen

Centra Inc. and subsidiaries
Consolidated comprehensive income statements
January 1 to March 31, 2026 and 2025

Unit: NTD thousand
(except EPS in NTD)

Item	Additional notes	January 1 to March 31, 2026		January 1 to March 31, 2025	
		Amount	%	Amount	%
4000 Operating revenues	6(21) and 7	\$ 2,228,857	100	\$ 2,255,628	100
5000 Operating cost	6(3)(25) and 7	(1,322,637)	(59)	(1,356,120)	(60)
5950 Operating gross profit		906,220	41	899,508	40
Operating expenses	6 (25)				
6100 Marketing expenses		(463,854)	(21)	(535,108)	(24)
6200 Administrative expenses		(119,854)	(6)	(107,865)	(5)
6300 Research and development expenses		(116,806)	(5)	(130,410)	(6)
6450 Expected credit impairment gain	12 (2)	1,780	-	21,939	1
6000 Total operating expenses		(698,734)	(32)	(751,444)	(34)
6900 Operating income		207,486	9	148,064	6
Non-operating revenues and expenses					
7100 Interest income	6(22) and 7	2,279	-	2,317	-
7010 Other income	6 (23)	10,206	1	5,171	-
7020 Other profits and losses	6 (24)	(685)	-	971	-
7050 Financial costs	6 (26)	(15,143)	(1)	(15,825)	(1)
7060 Shareholding in the affiliated companies and joint ventures under the equity method	6 (6)	37,688	2	6,931	1
7000 Total non-operating revenues and expenses		34,345	2	(435)	-
7900 Net profit before taxation		241,831	11	147,629	6
7950 Income tax expenses	6 (27)	(48,842)	(2)	(29,414)	(1)
8200 Net income		\$ 192,989	9	\$ 118,215	5

(Continued on next page)

Centra Inc. and subsidiaries
Consolidated comprehensive income statements
January 1 to March 31, 2026 and 2025

Unit: NTD thousand
(except EPS in NTD)

Item	Additional notes	January 1 to March 31, 2026		January 1 to March 31, 2025	
		Amount	%	Amount	%
Other comprehensive profit or loss (net)					
The items that are not re-classified as profit or loss					
8316	Unrealized valuation gains and losses on Investment of equity instruments at fair value through other comprehensive income	6(4)(20)			
		(\$ 17,802)	(1)	(\$ 3,238)	-
8320	The proportion of other comprehensive incomes from associates, and equity joint-ventures accounted for under the equity method – not reclassified as profit and loss	6 (20)			
		569	-	-	-
8310	Total amount of items not reclassified to profit or income	(17,233)	(1)	(3,238)	-
Items that may be re-classified subsequently under profit or loss					
8361	Exchange differences from the translation of financial statements of foreign operations	6 (20)			
		37,594	2	25,991	1
8370	The proportion of other comprehensive incomes from associates, and equity joint-ventures accounted for under the equity method – may be reclassified as profit and loss.	6 (20)			
		180	-	45	-
8399	Income tax related to items possibly be reclassified	6 (20) (27)			
		(7,518)	(1)	(5,198)	-
8360	Total amount of items probably reclassified to profit or loss subsequently				
		30,256	1	20,838	1
8300	Other comprehensive profit or loss (net)				
		\$ 13,023	-	\$ 17,600	1
8500	Current period other comprehensive income (Gross)				
		\$ 206,012	9	\$ 135,815	6
Net income (loss) attributable to:					
8610	Owners of parent				
		\$ 195,893	9	\$ 117,994	5
8620	Non-controlling interest				
		(2,904)	-	221	-
		\$ 192,989	9	\$ 118,215	5
Total comprehensive income attributable to:					
8710	Owners of parent				
		\$ 208,916	9	\$ 135,594	6
8720	Non-controlling interest				
		(2,904)	-	221	-
		\$ 206,012	9	\$ 135,815	6
Earnings per share					
9750	Basic earnings per share	6 (28)			
			1.57		0.93
9850	Diluted earnings per share		1.57		0.93

Please refer to the notes enclosed in the consolidated financial reports that are an integral part of the consolidated financial statements.

Chairman: Wang Ming-Ning Memorial Foundation Manager: Wang, Hou-Kai Accounting Supervisor: Hiang, Hsien-Chieh
Representative: Wang Hsien, I-Chen

Cenra Inc. and subsidiaries
Consolidated statement of changes in equity
January 1 to March 31, 2026 and 2025

Unit: NTD thousand

Additional notes	Equity of the parent company														Total	Non-controlling interest	Total equity
	Capital surplus					Retained earnings				Other equity							
	Common stock capital	Capital surplus-issuance premium	Treasury stock trade	Others	Employee restricted stock	Legal reserve	Special reserve	Unappropriated Retained Earnings	Exchange differences from the translation of financial statements of foreign operations	Unrealized gain or loss on financial assets at fair value through other comprehensive profit or loss	Unearned Employee Compensation	Treasury stock					
January 1 to March 31, 2025																	
Balance at January 1	\$ 1,490,405	\$ 5,901,560	\$ 68,087	\$ 1,956	\$ -	\$ -	\$ 188,958	\$ 113,624	(\$ 85,170)	(\$ 137,597)	\$ -	(\$ 32,304)	\$ 7,509,519	\$ 39,832	\$ 7,549,351		
Net income	-	-	-	-	-	-	-	117,994	-	-	-	-	117,994	221	118,215		
Current period other comprehensive income	6(4)(20)	-	-	-	-	-	-	-	20,838	(3,238)	-	-	17,600	-	17,600		
Current period other comprehensive income (Gross)		-	-	-	-	-	-	117,994	20,838	(3,238)	-	-	135,594	221	135,815		
Equity instrument at fair value through other comprehensive income statement	6(4)(20)	-	-	-	-	-	-	(61,981)	-	61,981	-	-	-	-	-		
Repurchase of treasury stock		-	-	-	-	-	-	-	-	-	-	(34,101)	(34,101)	-	(34,101)		
Balance at March 31	\$ 1,490,405	\$ 5,901,560	\$ 68,087	\$ 1,956	\$ -	\$ -	\$ 188,958	\$ 169,637	(\$ 64,332)	(\$ 78,854)	\$ -	(\$ 66,405)	\$ 7,611,012	\$ 40,053	\$ 7,651,065		
January 1 to March 31, 2026																	
Balance at January 1	\$ 1,497,656	\$ 5,812,204	\$ 68,389	\$ 9,562	\$ 17,692	\$ 11,362	\$ 222,767	\$ 252,494	(\$ 82,116)	(\$ 71,642)	(\$ 20,083)	(\$ 146,631)	\$ 7,571,654	\$ 39,978	\$ 7,611,632		
Net income	-	-	-	-	-	-	-	195,893	-	-	-	-	195,893	(2,904)	192,989		
Current period other comprehensive income	6(4)(20)	-	-	-	-	-	-	-	30,256	(17,233)	-	-	13,023	-	13,023		
Current period other comprehensive income (Gross)		-	-	-	-	-	-	195,893	30,256	(17,233)	-	-	208,916	(2,904)	206,012		
Equity instrument at fair value through other comprehensive income statement	6(4)(20)	-	-	-	-	-	-	(2,849)	-	2,849	-	-	-	-	-		
Cost of share-based remuneration	6(16)(20)	-	-	-	-	-	-	-	-	-	2,997	-	2,997	-	2,997		
Balance at March 31	\$ 1,497,656	\$ 5,812,204	\$ 68,389	\$ 9,562	\$ 17,692	\$ 11,362	\$ 222,767	\$ 445,538	(\$ 51,860)	(\$ 86,026)	(\$ 17,086)	(\$ 146,631)	\$ 7,783,567	\$ 37,074	\$ 7,820,641		

Please refer to the notes enclosed in the consolidated financial reports that are an integral part of the consolidated financial statements.

Centra Inc. and subsidiaries
Consolidated cash flow statement
January 1 to March 31, 2026 and 2025

Unit: NTD thousand

	Additional notes	January 1 to March 31, 2026		January 1 to March 31, 2025
<u>Cash flow from operating activities</u>				
Current year net profit before taxation		\$ 241,831	\$	147,629
Adjustments				
Profits and loss				
Depreciation expenses	6 (24) (25)	86,875		83,933
Amortization expenses	6 (25)	2,176		2,724
Share-based payment	6 (16) (25)	2,997		-
Expected credit impairment gain	12 (2)	(1,780)	(21,939)
Decrease of allowance for sales return and allowance		(22,778)	(3,909)
Interest expenses	6 (26)	15,143		15,825
Interest income	6 (22)	(2,279)	(2,317)
Shareholding in the affiliated companies and joint ventures under the equity method	6 (6)	(37,688)	(6,931)
Gain in disposal of real estate, plant buildings, equipment & facilities	6 (24)	-	(22)
Changes in assets/liabilities relating to operating activities				
Net changes in assets relating to operating activities				
Accounts receivable (including related party and non-related party)		(12,168)	(38,033)
Bills receivable (including related party and non-related party)		50,898		78,673
Finance lease receivables		160		-
Other account receivable (including related party and non-related party)		(13,388)	(26,945)
Inventory		108,246		153,342
Other current assets		(21,946)	(14,184)
Net changes in liabilities relating to operating activities				
Contractual liability- liquidity		28,520		5,638
Payable notes		(11)	(755)
Accounts payable		8,357	(142,903)
Other payables		(143,050)	(96,991)
Refund liability - liquidity		(36,860)	(25,526)
Other current liabilities- other		6,839	(2,500)
Other non-current liabilities		(491)	(618)
Cash inflow from operating activities		259,603		158,081
Interest received		1,674		1,618
Interest payment		(14,901)	(16,616)
Income tax payment		(698)	(9,469)
Income tax refund		-		2,975
Net cash inflow from operating activities		245,678		136,589

(Continued on next page)

Centra Inc. and subsidiaries
Consolidated cash flow statement
January 1 to March 31, 2026 and 2025

Unit: NTD thousand

	<u>Additional notes</u>	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
<u>Cash flow from investing activities</u>			
Acquisition of financial assets at fair value through other comprehensive profit or loss		(\$ 66,060)	(\$ 97)
Value of disposal of financial assets measured at FVTOCI	6 (4)	2,101	139,653
Acquisition of returned share capital from decrease in financial assets at fair value through other comprehensive income	6 (4)	7,442	-
Acquisition of investment under the equity method	7	-	(463)
Purchase of property, plant, and equipment	6 (29)	(55,303)	(41,582)
Proceeds from disposal of property, plant and equipment		2	130
Purchase of intangible assets		(2,590)	(116)
Increase of the financing amount receivable		(1,500)	(28,000)
Increase in refundable deposits		(2,567)	(2,358)
Decrease in other non-current assets		<u>4,905</u>	<u>6,982</u>
Net cash inflow (outflow) from investing activities		<u>(113,570)</u>	<u>74,149</u>
<u>Cash flow from financing activities</u>			
Increase in Shot-term borrowings	6(30)	50,042	395,395
Increase of short-term notes payable	6(30)	30,000	418,008
Lease principal repayment	6(30)	(13,562)	(12,369)
Current repaying amount of long-term loan	6(30)	(10,400)	(826,300)
Decrease (increase) in deposits received	6(30)	(1,737)	(1,559)
Repurchase of treasury stock		<u>-</u>	<u>(34,101)</u>
Net cash inflow (outflow) from financing activities		<u>54,343</u>	<u>(60,926)</u>
Impact of changes in exchange rate on cash and cash equivalents		<u>(15,809)</u>	<u>7,271</u>
Current cash and cash equivalents increase		170,642	157,083
Balance of cash and cash equivalents, beginning of period		<u>729,497</u>	<u>588,011</u>
Balance of cash and cash equivalent, end of period		<u>\$ 900,139</u>	<u>\$ 745,094</u>

Please refer to the notes enclosed in the consolidated financial reports that are an integral part of the consolidated financial statements.

Chairman: Wang Ming-Ning Memorial Foundation Manager: Wang, Hou-Kai Accounting Supervisor: Hiang, Hsien-Chieh
Representative: Wang Hsien, I-Chen

Cenra Inc. and subsidiaries
Notes to consolidated financial statement
Q1 2026 and 2025

Unit: NTD thousand
(Except where otherwise stated)

1. Company history

- (1) The Company was established on September 2, 2024, listed on the TWSE on the same day, and renamed Cenra Inc. on July 9, 2025.
- (2) On May 28, 2024, China Chemical & Pharmaceutical Co., Ltd. (hereinafter referred to as “CCPC”) resolved to apply for the establishment of the Company at the shareholders’ meeting and the meeting of the Company’s founders. The Company acquired 100% of the equity of CCPC through a share swap. The consideration for the share swap was 0.5 shares of the Company for every 1 share of CCPC. The Company completed the share swap transaction on September 2, 2024. CCPC became a wholly owned subsidiary of the Company and ceased its listing and public offering. The Company’s common stock shares are listed on the Taiwan Stock Exchange (TWSE) on the same day with the stock code of “3716.”
- (3) The Company and its subsidiary (hereinafter referred to as “The Group”) have major business in manufacturing and selling pharmaceutical products and health products, as well as the import business of related medical appliances.

2. Financial statements approval date and procedure

These consolidated financial statements were authorized by the Board of Directors on May 5, 2026.

3. Application of New Standards, Amendments and Interpretations

- (1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS”) as endorsed and issued into effect by the Financial Supervisory Commission (“FSC”)

The new publication, amendments, and revision of the 2026 International Financial Reporting Standards (IFRS) that was endorsed and issued into effect by the Financial Supervisory Commission are as follows:

New releases / amendments / revisions of the Standards and Interpretations	The effective date announced by the International Accounting Standards Board
Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”	January 1, 2026
Amendments to IFRS 9 and IFRS 7, “Contracts Referencing Nature-dependent Electricity”	January 1, 2026
IFRS 17 “Insurance Contracts”	January 1, 2023
Amendments to IFRS 17 “Insurance Contracts”	January 1, 2023
Amendments to IFRS 17 - Application of IFRS 17 and IFRS 9 — Comparative Information	January 1, 2023
Annual Improvements to IFRSs—Volume 11	January 1, 2026

The Group has assessed the aforementioned standards, interpretations, and interpretative announcements and has concluded that they have no material impact on the Group’s financial position and financial performance.

- (2) Effect of new issuances of or amendments to IFRS as endorsed by the FSC but not yet adopted by the Company and subsidiaries
None.
- (3) IFRS issued by IASB but not yet endorsed by the FSC
The newly released, revised and amended IFRS standards and interpretations by the IASB but not yet recognized by the FSC are summarized as follows:

New releases / amendments / revisions of the Standards and Interpretations	The effective date announced by the International Accounting Standards Board
Amendment to IFRS 10 and IAS 28 “The Assets Sales or Purchase between Investors and Their Affiliates or Joint Ventures”	To be determined by the “International Accounting Standards Board (IASB).”
IFRS 18 “Presentation and Disclosure in Financial Statements”	January 1, 2027 (Note)
IFRS 19 “Subsidiaries without Public Accountability: Disclosures”	January 1, 2027
Amendments to IAS No. 21 “Translation to a Hyperinflationary Presentation Currency”	January 1, 2027

Note: In the press release dated September 25, 2025, the FSC announced that publicly-issued companies shall apply International Financial Reporting Standard 18 (the “IFRS 18”) from 2028 onward; in addition, if a company intends to apply IFRS 18 earlier, it could do so after IFRS 18 has been endorsed by the FSC.

Except for the following statements, the Group has assessed the aforementioned standards, interpretations, and interpretative announcements and has concluded that they have no material impact on the Group’s financial position and financial performance:

IFRS 18 “Presentation and Disclosure in Financial Statements”

IFRS 18 “Presentation and Disclosure in Financial Statements” has replaced IAS 1, updating the structure of the statement of comprehensive income, and adding the disclosure of management performance measurements, while strengthening the summary and division of the use in the main financial statements and notes.

4. Summary of significant accounting policies

The significant accounting policies, except for the statement of compliance, the basis of preparation, the basis of consolidation, and the new parts are as follows, which are the same as Note 4 to the consolidated financial statements of 2025. These policies have been consistently applied to all the period presented, unless otherwise stated.

(1) Compliance Statement

1. These consolidated financial statements are prepared in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” and the International Accounting Standards and IAS 34 “Interim Financial Reporting”.
2. The consolidated financial statements shall be read together with the 2025 consolidated financial statements.

(2) Basis of preparation

1. Except for the following items, these consolidated statements have been prepared under the historical cost convention:
 - (1) Financial assets measured at fair value through profit or loss (including derivatives).
 - (2) Financial assets at fair value through other comprehensive income
 - (3) Defined benefit assets and liabilities recognized at the net amount of pension fund assets less the present value of defined benefit obligations.
2. The financial statements prepared in accordance with the International Financial Reporting Standards, international accounting standards, interpretation and interpretation notice (referred to as “IFRS” hereinafter) that is endorsed and issued into effect by the FSC requires the use of some critical accounting estimates; also, the judgment by the management is required while using the Group’s accounting policies. Please refer to Note 5 for the items involving extensive judgment or complexity, or significant assumptions and estimates related to the consolidated financial statements.

(3) Basis of consolidation

1. The basis of preparation for consolidated financial statements
The preparation principles of the consolidated financial statements are the same as those of the 2025 consolidated financial statements.
2. Subsidiaries included in the financial statements:

Investor	Name of the subsidiary	Nature of the operation	Percentage of shareholdings (%)			Remarks
			March 31, 2026	December 31, 2025	March 31, 2025	
Cenra Inc.	China Chemical & Pharmaceutical Co., Ltd. (CCPC)	Manufacture and sales of Western medicine preparations and health-care articles.	100.00	100.00	100.00	Note 2
Cenra Inc.	Chunghwa Yuming Healthcare Co., Ltd. (Chunghwa Yuming)	Wholesale of medicine and medical equipment	100.00	-	-	Note 5
Cenra Inc.	Providence Investments Inc.	General investment businesses	100.00	-	-	Note 1 and Note 4
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Yuming Healthcare Co., Ltd. (Chunghwa Yuming)	Wholesale of medicine and medical equipment	-	100.00	100.00	Note 5
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Senior Lifestyle Services Co. Ltd. (Chunghwa Senior Lifestyle Services)	Medicine, wholesale of medicine equipment and home care service	100.00	100.00	100.00	Note 1
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Holding Co.,Ltd. (Chunghwa)	Professional investment company	100.00	100.00	100.00	
China Chemical & Pharmaceutical Co., Ltd.	Tairung Enterprise Co., Ltd. (Tairung)	Manufacture and sales of glass, plastics made containers	71.64	71.64	71.64	Note 1
Chunghwa Yuming Healthcare Co., Ltd.	Chunghwa Biomedical Technology Corp.	Manufacturer of cleaning products	75.23	75.23	73.96	Note 1
Chunghwa Holding Co.,Ltd.	Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.(SCCPC)	Manufacture and sales of pharmaceutical medicine and health products.	100.00	100.00	100.00	
Suzhou Chung-Hwa	Suzhou Chunghwa	Wholesale and sales	100.00	100.00	100.00	Note 1

Investor	Name of the subsidiary	Nature of the operation	Percentage of shareholdings (%)			Remarks
			March 31, 2026	December 31, 2025	March 31, 2025	
Chemical & Pharmaceutical Industrial Co., Ltd.	Yuming Pharmaceutical Co., Ltd.	of pharmaceutical medicine and medical equipment.				
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Shanghai Yuhou Trading Co., Ltd. (formerly known as Pei Fu (Shanghai) Co., Ltd.)	Wholesale and sales of medical equipment.	100.00	100.00	100.00	Note 1
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Suzhou Chung-Hwa Le Huo Jian Kang Co., Ltd.	E-commerce sales of health products	100.00	100.00	100.00	Note 1
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Chung-Hwa Le Huo Jian Kang (HK) Co., Ltd.	Biotech products sold as an agent	100.00	100.00	100.00	Note 3

Note 1: Chung-Hwa Le Huo Jian Kang (HK) Co., Ltd. not yet invested capital as of March 31, 2026.

Note 2: Providence Investments was established on June 5, 2025.

Note 3: On June 30, 2025, CCPC was reorganized and restructured, with Cenra holding 100% shares held of Chunghwa Yuming Healthcare.

3. Subsidiary company not included in the consolidated financial statements are as follows: Not applicable.
4. Adjustments on subsidiary companies with different accounting periods: Not applicable.
5. Significant limitations: Not applicable.
6. Subsidiaries over which the group has significant influence but not control: none

(4) Employee benefits

Pension - defined benefit plan

The interim pension cost is calculated based on the actuarial pension cost rate on the last day of the previous fiscal year from the beginning of the year to the end of the period. If there is a significant market change, significant reduction, settlement, or other significant one-time event after the end date, it is adjusted and the relevant information is correspondingly disclosed.

(5) Income tax

The average effective tax rate used to estimate the interim income tax expense shall be applicable to the interim income before tax, and the relevant information is correspondingly disclosed.

5. Critical accounting judgments, estimates and key sources of assumption uncertainty

There is no significant change in the current period. Please refer to Note 5 to the 2025 consolidated financial statements.

6. Summary of significant accounting titles

(1) Cash and cash equivalents

	March 31, 2026	December 31, 2025	March 31, 2025
Cash on hand	\$ 4,257	\$ 4,046	\$ 3,619
Check deposit and demand deposits	849,582	680,541	700,309
Cash equivalents- time deposits	<u>46,300</u>	<u>44,910</u>	<u>41,166</u>
	<u>\$ 900,139</u>	<u>\$ 729,497</u>	<u>\$ 745,094</u>

1. The financial institutions that the Group deals with are with good credit quality; also, the Group deals with a number of financial institutions to diversify credit risk; therefore, the possibility of default is very unlikely.

2. None of the Group's cash and cash equivalents pledged to others as collateral.

(2) Note receivable and accounts receivable

	March 31, 2026	December 31, 2025	March 31, 2025
Notes receivable	\$ 293,027	\$ 334,422	\$ 350,531
Less: Allowance for losses	<u>(311)</u>	<u>(436)</u>	<u>(779)</u>
	<u>\$ 292,716</u>	<u>\$ 333,986</u>	<u>\$ 349,752</u>
Accounts receivable	\$ 1,630,601	\$ 1,622,252	\$ 1,627,207
Less: Allowance for sales and discount	<u>(121,834)</u>	<u>(144,612)</u>	<u>(126,128)</u>
Less: Allowance for losses	<u>(10,724)</u>	<u>(11,315)</u>	<u>(7,491)</u>
	<u>\$ 1,498,043</u>	<u>\$ 1,466,325</u>	<u>\$ 1,493,588</u>

1. The aging analysis of accounts receivable and bill receivable is as follows:

	March 31, 2026		December 31, 2025	
	Accounts receivable	Notes receivable	Accounts receivable	Notes receivable
Not-overdue	\$ 1,559,496	\$ 292,464	\$ 1,573,177	\$ 333,642
Overdue within 1-90 days	65,441	563	41,548	780
Overdue within 91-180 days	2,716	-	4,320	-
Overdue exceeding 181 days	<u>2,948</u>	<u>-</u>	<u>3,207</u>	<u>-</u>
	<u>\$ 1,630,601</u>	<u>\$ 293,027</u>	<u>\$ 1,622,252</u>	<u>\$ 334,422</u>

	March 31, 2025	
	Accounts receivable	Notes receivable
Not-overdue	\$ 1,595,516	\$ 350,531
Overdue within 1-90 days	26,179	-
Overdue within 91- 180 days	3,065	-
Overdue exceeding 181 days	<u>2,447</u>	<u>-</u>
	<u>\$ 1,627,207</u>	<u>\$ 350,531</u>

The aforementioned aging analysis is based on the overdue days.

2. Account and note receivables as of March 31, 2026, December 31 and March 31, 2026 were from customer contracts. Account receivables (including note receivables) and the associated allowed made stood at \$1,795,434 and \$12,153, respectively, on January 1, 2025.
 3. The exposure amounts of the maximum credit risk which can represent the accounts receivable and bill receivable of the Group without considering the possessed collateral or other credit enhancement condition on March 31, 2026, December 31 and March 31, 2025 are its book amount.
 4. The accounts receivable listed in the account of the Group does not possess any collateral.
 5. Please find Note 12 (2) for the relevant explanation about credit risk.
- (3) Inventory

	March 31, 2026		
	Cost	Allowance for loss from price declination	Book value
Raw materials	\$ 962,062	(\$ 12,257)	\$ 949,805
Material	194,433	(3,266)	191,167
Work in process	371,796	(3,882)	367,914
Finished products	577,258	(24,909)	552,349
Merchandise inventory	<u>591,204</u>	<u>(31,433)</u>	<u>559,771</u>
	<u>\$ 2,696,753</u>	<u>(\$ 75,747)</u>	<u>\$ 2,621,006</u>
	December 31, 2025		
	Cost	Allowance for loss from price declination	Book value
Raw materials	\$ 985,945	(\$ 11,338)	\$ 974,607
Material	187,178	(1,544)	185,634
Work in process	344,239	(1,167)	343,072
Finished products	611,979	(19,178)	592,801
Merchandise inventory	<u>649,198</u>	<u>(36,653)</u>	<u>612,545</u>
	<u>\$ 2,778,539</u>	<u>(\$ 69,880)</u>	<u>\$ 2,708,659</u>

	March 31, 2025		
	Cost	Allowance for loss from price declination	Book value
Raw materials	\$ 981,258	(\$ 5,205)	\$ 976,053
Material	180,424	(1,059)	179,365
Work in process	357,643	(2,541)	355,102
Finished products	615,596	(32,352)	583,244
Merchandise inventory	647,125	(40,087)	607,038
	<u>\$ 2,782,046</u>	<u>(\$ 81,244)</u>	<u>\$ 2,700,802</u>

The cost of inventory recognized as expense of The Group within the current period:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Cost of inventory sold	\$ 1,284,387	\$ 1,330,936
Labor service cost	31,268	27,849
Loss (Revesal) on inventory Valuation	6,231	(4,114)
Loss on disposal of inventory	751	1,449
	<u>\$ 1,322,637</u>	<u>\$ 1,356,120</u>

From January 1 to March 31, 2025, as the market prices of some of the Group's inventory recovered and the inventories that had been recognized in depreciation losses in prior years were scrapped, it was recognized in gain from price recovery.

(4) Financial assets at fair value through other comprehensive profit or loss

<u>Item</u>	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Non-current items:			
Equity instruments			
Listed stocks	\$ 108,276	\$ 63,792	\$ 96,530
Non-listed shares, OTC, emerging stocks	<u>96,334</u>	<u>102,704</u>	<u>92,064</u>
	<u>\$ 204,610</u>	<u>\$ 166,496</u>	<u>\$ 188,594</u>

1. The Group decides to classify the stock of strategic as investment financial assets at fair value through other comprehensive income.
2. For the three months ended March 31, 2026, capital reduction and refund of the Group's investment in financial assets measured at fair value through other comprehensive income amounted to \$7,442.
3. For the three months ended March 31, 2026, the Group sold equity investments with a fair value of \$2,101, transferring \$2,849 from other equity to retained earnings. The cumulative loss on disposal of these investments was \$ (2,849). For the three months ended March 31,

2026, the Group sold stock investments with a fair value of \$139,653, reclassifying \$61,981 from other equity to retained earnings. The cumulative disposal loss on the investment was \$ (61,981).

4. The details of financial assets at fair value through other comprehensive income which recognized in income and comprehensive income are as follows:

<u>Item</u>	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
<u>Equity measured at fair value through other comprehensive income</u>		
Recognized in comprehensive income of changes in fair value.		
The party still in possession at the end of this term.	(\$ 17,233)	(\$ 3,238)
The accumulated losses change to retained earnings (post-tax profit or loss)		
Due to the reclassification of removed items	(\$ 2,849)	(\$ 61,981)

(5) Financial assets measured at the amortized cost

<u>Item</u>	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Current items:			
Time deposits	\$ -	\$ -	\$ 98,168
Non-current items:			
Time deposits	\$ 139,513	\$ 134,866	\$ -

1. Financial assets measured on the basis of amortized cost is recognized as income and specified as follows:

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
Interest income	\$ 605	\$ 699

2. In the absence of collateral or other credit enhancement, the maximum amount of credit risk exposure of the symbolic financial assets measured on the basis of amortized cost held by the Group was \$139,513, \$134,866 and \$98,168, respectively as of March 31, 2026, March 31 and December 31, 2025.

3. The Group did not pledge any financial assets measured on the basis of amortized cost under lien.

4. For additional information on the financial assets measured on the basis of amortized cost, refer to Note 12, (2). The Group invests the certificates of deposits only with financial institutions in good credit standing. Default is unlikely to occur.

(6) Investment under the equity method

Name of investee	March 31, 2026	December 31, 2025	March 31, 2025
Affiliated enterprises:			
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB)	\$ 922,378	\$ 903,990	\$ 984,493
Sino-Japan Chemical Co., Ltd. (Sino-Japan Chemical)	536,202	516,506	530,866
PHERMPEP CO., LTD. (PHERMPEP)	6,795	6,442	2,656
Wuxi Jirui Medical Technology Co., Ltd. (Wuxi Jirui)	1,969	1,911	4,468
	\$ 1,467,344	\$ 1,428,849	\$ 1,522,483

1. Affiliated enterprises

(1) Basic information of significant associate of the Group is as follows:

Company name	Major places of business	Ratio of Shareholding		Nature of relationship	Measuring method
		March 31, 2026	December 31, 2025		
CCSB	Taiwan	28.05%	28.05%	Suppliers	Equity method
SINO-JAPAN CHEMICAL	Taiwan	21.99%	21.99%	Financial investment	Equity method

Company name	Major places of business	Ratio of Shareholding		
		March 31, 2025	Nature of relationship	Measuring method
CCSB	Taiwan	27.82%	Suppliers	Equity method
SINO-JAPAN CHEMICAL	Taiwan	21.99%	Financial investment	Equity method

(2) Financial information of the Group's major associates is summarized as follows:

Balance Sheet

	CCSB		
	March 31, 2026	December 31, 2025	March 31, 2025
Current assets	\$ 1,211,119	\$ 1,058,883	\$ 1,418,113
Non-Current assets	3,244,967	3,258,470	3,327,000
Current liabilities	(401,638)	(356,706)	(492,603)
Non-current liabilities	(874,332)	(873,307)	(876,876)
Total net assets	<u>\$ 3,180,116</u>	<u>\$ 3,087,340</u>	<u>\$ 3,375,634</u>
Book value of the associate	<u>\$ 922,378</u>	<u>\$ 903,990</u>	<u>\$ 984,493</u>

	SINO-JAPAN CHEMICAL		
	March 31, 2026	December 31, 2025	March 31, 2025
Current assets	\$ 2,358,192	\$ 2,292,150	\$ 2,354,617
Non-Current assets	634,756	615,861	593,913
Current liabilities	(383,444)	(407,183)	(346,470)
Non-current liabilities	(83,605)	(64,511)	(100,436)
Total net assets	<u>\$ 2,525,899</u>	<u>\$ 2,436,317</u>	<u>\$ 2,501,624</u>
Book value of the associate	<u>\$ 536,202</u>	<u>\$ 516,506</u>	<u>\$ 530,866</u>

Comprehensive income statement

	CCSB	
	January 1 to March 31, 2026	January 1 to March 31, 2025
Income	\$ 361,225	\$ 192,952
Current year profit of continuing business units	\$ 90,601	\$ 7,318
Other comprehensive income (post-tax profit or loss)	2,175	11,376
Current period other comprehensive income	\$ 92,776	\$ 18,694

	SINO-JAPAN CHEMICAL	
	January 1 to March 31, 2026	January 1 to March 31, 2025
Income	\$ 723,358	\$ 617,332
Current year profit of continuing business units	\$ 89,582	\$ 51,231
Current period other comprehensive income	\$ 89,582	\$ 51,231

- (3) The share of the operating results of individual insignificant associates of the Group is summarized as follows:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Net loss of current period	(\$ 169)	(\$ 1,306)

- (4) The shares of profit and/or loss at equity method over the associates as follows:

Name of affiliated enterprise	January 1 to March 31, 2026	January 1 to March 31, 2025
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	\$ 18,161	(\$ 3,027)
SINO-JAPAN CHEMICAL., CO., LTD	19,696	11,264
PHERMPEP CO., LTD.	(167)	(1,304)
Wuxi Jirui Medical Technology Co., Ltd.	(2)	(2)
	\$ 37,688	\$ 6,931

- (5) The significant associate of the Group-CCSB is public offering and its fair values of March 31, 2026, December 31 and March 31, 2025 are, respectively, \$705,505, \$720,607 and \$ 773,466.
- (6) The company holds 28.05% equity of CCSB and is the largest shareholder of CCSB. Considering the participation of other shareholders in the previous shareholders meeting of CCSB and the record of voting rights casted on major proposals, it indicates that the Group is incapable of leading relevant activities. Therefore, it has no control over CCSB, but a significant influence.

(7) Property, plant, and equipment

		2026						
		Land	Buildings and structures	Machinery equipment	Transport equipment	Construction in process and equipment to be inspected	Others	Total
January 1								
Cost		\$ 1,021,812	\$ 3,529,191	\$ 1,698,379	\$ 41,557	\$ 78,017	\$ 1,412,228	\$ 7,781,184
Accumulated depreciation		-	(1,766,784)	(1,055,360)	(32,329)	-	(974,188)	(3,828,661)
		<u>\$ 1,021,812</u>	<u>\$ 1,762,407</u>	<u>\$ 643,019</u>	<u>\$ 9,228</u>	<u>\$ 78,017</u>	<u>\$ 438,040</u>	<u>\$ 3,952,523</u>
January 1		\$ 1,021,812	\$ 1,762,407	\$ 643,019	\$ 9,228	\$ 78,017	\$ 438,040	\$ 3,952,523
Additions		-	1,263	2,661	222	24,109	5,730	33,985
Transfer		-	1,617	16,202	-	(19,891)	2,072	-
Disposal		-	-	-	-	-	(2)	(2)
Depreciation expenses		-	(26,552)	(21,070)	(917)	-	(22,888)	(71,427)
Net exchange differences		-	2,536	2,565	63	318	1,733	7,215
March 31		<u>\$ 1,021,812</u>	<u>\$ 1,741,271</u>	<u>\$ 643,377</u>	<u>\$ 8,596</u>	<u>\$ 82,553</u>	<u>\$ 424,685</u>	<u>\$ 3,922,294</u>
March 31								
Cost		\$ 1,021,812	\$ 3,536,351	\$ 1,729,003	\$ 42,150	\$ 82,553	\$ 1,429,969	\$ 7,841,838
Accumulated depreciation		-	(1,795,080)	(1,085,626)	(33,554)	-	(1,005,284)	(3,919,544)
		<u>\$ 1,021,812</u>	<u>\$ 1,741,271</u>	<u>\$ 643,377</u>	<u>\$ 8,596</u>	<u>\$ 82,553</u>	<u>\$ 424,685</u>	<u>\$ 3,922,294</u>

		2025						
		Land	Buildings and structures	Machinery equipment	Transport equipment	Construction in process and equipment to be inspected	Others	Total
January 1								
Cost		\$ 1,021,812	\$ 3,577,674	\$ 1,610,150	\$ 41,681	\$ 113,032	\$ 1,372,199	\$ 7,736,548
Accumulated depreciation		-	(1,727,106)	(988,606)	(33,458)	-	(910,063)	(3,659,233)
		<u>\$ 1,021,812</u>	<u>\$ 1,850,568</u>	<u>\$ 621,544</u>	<u>\$ 8,223</u>	<u>\$ 113,032</u>	<u>\$ 462,136</u>	<u>\$ 4,077,315</u>
January 1		\$ 1,021,812	\$ 1,850,568	\$ 621,544	\$ 8,223	\$ 113,032	\$ 462,136	\$ 4,077,315
Additions		-	2,105	18,679	300	5,459	-	26,543
Transfer		-	2,002	35,667	20	(50,308)	12,619	-
Disposal		-	-	-	(89)	-	(19)	(108)
Depreciation expenses		-	(26,132)	(20,063)	(719)	-	(22,511)	(69,425)
Net exchange differences		-	2,018	1,843	61	220	1,268	5,410
March 31		<u>\$ 1,021,812</u>	<u>\$ 1,830,561</u>	<u>\$ 657,670</u>	<u>\$ 7,796</u>	<u>\$ 68,403</u>	<u>\$ 453,493</u>	<u>\$ 4,039,735</u>
March 31								
Cost		\$ 1,021,812	\$ 3,584,717	\$ 1,672,685	\$ 41,722	\$ 68,403	\$ 1,386,585	\$ 7,775,924
Accumulated depreciation		-	(1,754,156)	(1,015,015)	(33,926)	-	(933,092)	(3,736,189)
		<u>\$ 1,021,812</u>	<u>\$ 1,830,561</u>	<u>\$ 657,670</u>	<u>\$ 7,796</u>	<u>\$ 68,403</u>	<u>\$ 453,493</u>	<u>\$ 4,039,735</u>

- Notes: 1. Please refer to Note 8 for the information on the property, plant, and equipment provided as collateral.
2. When the Group obtains government subsidies for property, plant and equipment, it is debited to the carrying amount and recognized in profit or loss through a decrease in depreciation expenses over the useful life of the asset.
3. The Group rented the land of No. 23, Xiangyang Rd., Taipei City from Jen-Chi Relief Institution, the lease term is from January 1, 2015 to December 31, 2029 with the rental of \$322 paid by the month. According to contractual requirement, if the contract is not renewed at expiration, the construction on the lease land shall unconditionally be torn down and the land should be returned. As of March 31 2026, the remaining balance of depreciation of the construction amounted to \$45,494.

(8) Lease transaction - lessee

1. Underlying assets leased by the Group include land, buildings, machinery and equipment, business vehicles, and office equipment, with lease terms generally ranging from one to fifty years. Lease agreements were negotiated individually with various terms and conditions. There are specific no restrictions specified, except that the leased assets cannot be used as loan guarantee.
2. Carrying amount and recognized amortization for right-of-use assets are as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
	<u>Book value</u>	<u>Book value</u>	<u>Book value</u>
Land	\$ 48,375	\$ 47,128	\$ 50,351
Buildings	252,418	261,721	265,947
Machinery equipment	39,477	39,327	43,216
Delivery facilities (business vehicles)	4,801	5,795	8,834
Furniture and fixtures	14,311	15,151	-
	<u>\$ 359,382</u>	<u>\$ 369,122</u>	<u>\$ 368,348</u>

	January 1 to March 31, 2026	January 1 to March 31, 2025
	<u>Depreciation expenses</u>	<u>Depreciation expenses</u>
Land	\$ 1,002	\$ 973
Buildings	10,721	10,613
Machinery equipment	1,053	1,039
Delivery facilities (business vehicles)	994	1,050
Furniture and fixtures	839	-
	<u>\$ 14,609</u>	<u>\$ 13,675</u>

3. The Group's right-of-use assets for the three months ended March 31, 2026 and 2025 increased by \$ 3,036 and \$ 5,454 respectively.
4. Profit and loss items relating to lease contracts:

	January 1 to March 31, 2026	January 1 to March 31, 2025
<u>Profit and loss items with current impacts</u>		
Interest expense on the lease liability	\$ 1,732	\$ 1,711
Low-value leases expense	585	479
Short-term lease expense	6,935	3,865

5. The Group's total lease cash outflows for the three months ended March 31, 2026 and 2025 were \$ 22,814 and \$ 18,424, respectively.
 6. Options to extend lease
 - (1) Options to extend lease term are included in land leases for office buildings, which have helped increase operation agility for the Group.
 - (2) Upon determining lease term, the Group has factored in all facts and condition that would produce future economy incentives. Lease term will be reassessed in the case of significant events when the decision of whether to exercise the extension option or not exercise the termination option is affected.
 - (3) Given the assessment of exercising an option to extend the lease, the right-of-use assets and lease liabilities increased by \$ 0, \$ 16,492 and \$ 16,492 in March 31, 2026, December 31, and March 31, 2025, respectively.
 7. Sub-subsidiary, Suzhou Chung-Hua Chemical & Pharmaceutical has received a subsidy of \$ 110,460 (or CNY 22,950 thousand) from the local government industrial funding, which was to reduce the cost of the rights to use land (recorded as long-term prepaid rent). The subsidy was then transferred to "right-of-use asset" in 2019 and will be recognized as depreciation expenses under profit and loss throughout the lease term.
 8. As the Group has leased some buildings and is contractually obligated to dismantle, remove, or restore the location(s), the present value of the costs expected to be incurred in dismantling, removing, or restoring the location(s) was recognized in decommissioning liabilities as of March 31, 2026 and 2025. The decommissioning liabilities recognized by the Group totaled \$ 4,688 and \$ 4,621 (recognized in other non-current liabilities), and the amortized interest expense for the three months ended March 31, 2026 and 2025 were \$ 17.
- (9) Lease transaction - lessor
1. Underlying assets leased out by the Group include buildings, with lease terms generally of six years. The lease agreements were negotiated individually with various terms and conditions.
 2. The Group leases out buildings under finance leases. According to the clauses of the lease agreements, the lease term covers the majority of the underlying assets' economic lives. Profit and loss items relating to lease contracts:

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
Finance income from net investment in leases	<u>\$ 26</u>	<u>\$ -</u>

3. The maturity analysis of undiscounted lease payments leased by the Group under finance leases is as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Current year	\$ 556	\$ -	\$ -
Over the next year	743	742	-
Over the next two years	743	743	-
Over the next three years	743	743	-
Over the next four years	743	743	-
Over the next five years	743	743	-
Over the next six years	-	743	-
Total	<u>\$ 4,271</u>	<u>\$ 4,457</u>	<u>\$ -</u>

4. The information on the reconciliation of undiscounted lease payments leased by the Group under finance leases and the net investment in leases is as follows:

	March 31, 2026		December 31, 2025		March 31, 2025	
	Current	Non- Current	Current	Non- Current	Current	Non- Current
Undiscounted lease payments	\$ 743	\$ 3,528	\$ 743	\$ 3,714	\$ -	\$ -
Unearned finance income	(92)	(201)	(96)	(222)	-	-
Net investment in leases	<u>\$ 651</u>	<u>\$ 3,327</u>	<u>\$ 647</u>	<u>\$ 3,492</u>	<u>\$ -</u>	<u>\$ -</u>

(10) Other non-current assets

	March 31, 2026	December 31, 2025	March 31, 2025
Prepayments for equipment	\$ 89,265	\$ 82,671	\$ 34,904
Refundable deposits	78,259	75,600	58,351
Long-term pre-paid payment	-	-	36,856
Long-term prepayments	5,781	7,080	8,557
Prepaid intangible assets	74,649	102,090	110,775
Defined benefit assets	21,254	21,170	1,985
Other non-current assets- Other	5,177	9,060	11,645
Less: accumulated impairment	<u>-</u>	<u>-</u>	<u>(30,747)</u>
	<u>\$ 274,385</u>	<u>\$ 297,671</u>	<u>\$ 232,326</u>

The long-term prepaid goods and accumulated impairment are the result of subsidiary Chunghwa Yuming signing the distribution agreement for the new medicine with the vendor,

Regulon, in July 2011 with the total amount of EUR 1,800,000. As of December 31, 2017, Chung-Hwa Yuming paid \$36,856 (EUR 900,000), which was recognized as “other non-current assets — long-term prepayments.” However, after evaluation in 2015, Chung-Hwa Yuming realized the development of such new medicine is not as expected, therefore the recognition of impairment loss of \$ 30,747 was listed.

After seeking legal advice, Chung-Hwa Yuming determined that the estimated costs of international arbitration proceedings would be high and that the current operational and financial status of vendor Regulon remains unknown. Consequently, it was decided to cease pursuit of the payment, and the amount was written off in 2025.

(11) Short-term borrowings

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Financial institution loan			
Secured loan	\$ 873,405	\$ 1,084,000	\$ 1,176,384
Credit loan	<u>1,184,380</u>	<u>923,743</u>	<u>600,800</u>
	<u>\$ 2,057,785</u>	<u>\$ 2,007,743</u>	<u>\$ 1,777,184</u>
Interest rate collars	1.85%~2.545%	1.85%~2.545%	1.75%~2.545%

1. The interest expenses recognized in profit or loss for the three months ended March 31, 2026 and 2025 were \$ 10,381 and \$ 9,141, respectively.
2. By March 31, 2026, December 31 and March 31, 2025, besides the short-term loan amount as stated in Note 8, the Group has issued cashier's checks, respectively, with \$ 2,546,000, \$2,541,410 and \$1,833,200 as collateral.

(12) Short-term notes payable

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Commercial papers	<u>\$ 410,000</u>	<u>\$ 380,000</u>	<u>\$ 507,000</u>
Interest rate collars	1.55%~1.81%	1.55%~1.82%	1.50%~1.89%

1. The interest expenses recognized in profit or loss for the three months ended March 31, 2026 and 2025 were \$1,845 and \$3,086, respectively.
2. The short-term bill is guaranteed by the bills finance company and financial instrument which is issued for short-term capital use, by March 31, 2026, December 31 and March 31, 2025, the cashier's checks have been issued, respectively, with \$730,000, \$780,000 and \$780,000 as collateral for short-term bill receivable.

(13) Other payables

	March 31, 2026	December 31, 2025	March 31, 2025
Salary and bonus payables	\$ 215,630	\$ 346,293	\$ 235,719
Remuneration to employees and directors payable	91,464	69,403	82,000
Accrued expenses	153,620	186,523	207,593
Commission payable	47,759	54,380	68,166
Construction equipment account payable	20,540	34,776	24,482
Other payables	26,580	28,750	27,805
	<u>\$ 555,593</u>	<u>\$ 720,125</u>	<u>\$ 645,765</u>

(14) Long-term borrowings

	March 31, 2026	December 31, 2025	March 31, 2025
Financial institution loan			
Secured loans	\$ 230,400	\$ 240,800	\$ 289,200
Credit loan	-	-	200,000
	<u>230,400</u>	<u>240,800</u>	<u>489,200</u>
Less: long-term borrowing due within 12 months	-	-	(25,200)
	<u>\$ 230,400</u>	<u>\$ 240,800</u>	<u>\$ 464,000</u>
Interest rate collars	1.95%~2.01%	1.95%~2.01%	1.99%~2.278%

1. The interest expenses recognized in profit or loss for the three months ended March 31, 2026 and 2025 were \$1,163 and \$4,867, respectively.
2. The borrowing period for unsecured borrowings and secured borrowings is from 2026 to 2029.
3. The detail for the unused loan amount of The Group is as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Floating annual rate			
Maturing in one year or less	\$ 1,902,195	\$ 2,379,200	\$ 1,881,211
Mature beyond one year	620,000	825,000	1,130,000
	<u>\$ 2,522,195</u>	<u>\$ 3,204,200</u>	<u>\$ 3,011,211</u>

By March 31, 2026, December 31 and March 31, 2025, besides the long-term loan amount as stated in Note 8, the Group has issued cashier's checks, respectively, with \$470,000, \$720,000 and \$1,310,000 as collateral.

(15) Pension

1. (1) The Company and its domestic subsidiaries have a defined benefit pension plan in accordance with the "Labor Standards Act", covering all regular employees' service years prior to the enforcement of the Labor Pension Act on July 1, 2005 and service years thereafter of employees who chose to continue to be subject to the pension mechanism under the Law. When an employee meets the requirements of retirement, the payment of pension is based on service years and the average salary of the six months prior to retirement, with services within 15 years accumulating 2 basis points per year, and service years beyond 15 years accumulating 1 basis point per year up to a maximum of 45 basis points. The company and subsidiary companies provisions 2~6% of total monthly salary to the pension fund in the name of the Pension Supervisory Committee at the Bank of Taiwan. In addition, the Company and subsidiary have the labor pension reserve account balance referred to in the preceding paragraph estimated at the end of each fiscal year. If the account balance is insufficient to pay pension benefit to the employees who qualify for retirement within next year for the pension benefit calculated in the preceding paragraph, the Company and subsidiary will have the spread amount appropriated in a lump sum before the end of March next year.
- (2) For the three months ended March 31, 2026 and 2025, the net pension cost recorded by the company according to the above mentioned pension plans are \$25 and \$324 respectively.
- (3) The Group has appropriated \$2,322 to the pension plan in 2026.
2. (1) Since July 1, 2005, the company and domestic subsidiaries have established definitive provision pension scheme for employees with Taiwan nationality in accordance with the "Labor Pension Act". The Company and its domestic subsidiaries have established a defined contribution pension plan (the "New Plan") under the "Labor Pension Act" covering all regular employees. Under the New Plan, the Group contributes monthly an amount based on 6% of the employees' monthly salaries and wages to an employee's individual pension account at the Bureau of Labor Insurance. The payment of pension benefits is based on an employee's individual pension fund account and the cumulative profit in such account, and employees can choose to receive such pension benefits monthly or in one lump sum.
- (2) In terms of the pension insurance system of the SCCPC regulated by the government of the People's Republic of China, pension insurance premiums based on a certain percentage of the total salary of local employees are appropriated every month. The ratio are 16% for the three months ended March 31, 2026 and 2025. The pension of each employee is arranged by the government. The Group has no further obligations other than appropriating the pension each month.
- (3) For the three months ended March 31, 2026 and 2025, the net pension cost recorded by the company according to the above mentioned pension plans are \$26,627 and \$26,137 respectively.

(16) Share-based payment

1. The Group's share-based payment arrangement for March 31, 2026 is as follows:

<u>Type of arrangement</u>	<u>Grant date</u>	<u>Amount granted (thousand shares)</u>	<u>Contract term</u>	<u>Vesting conditions</u>
New restricted employee shares plan - A	2025.8.8	725	3 years	Note

New restricted employee shares issued by the Group shall be transferred during the vesting period, and they shall not participate in or obtain the following related options before the vesting conditions are met, including but not limited to the right to receive dividends, bonuses, capital reserves, and cash capital increase warrants. If an employee resigns or dies, the new restricted employee shares not yet vested shall be deemed not to meet the vesting conditions on the effective date of resignation or the date of death. The Group will recall the shares without consideration and cancel them.

Note: A portion of the new restricted employee shares vests immediately at 33% after one or two years of service, while the remaining 34% vests after three years of service. The proportion of vested shares is calculated once every three years after the grant. The proportion of vested shares is calculated based on the achievement of the Company's operating performance indicators.

2. Details of the abovementioned share-based payment arrangement are as follows (unit: thousand shares):

	<u>2026</u>	<u>2025</u>
Number of outstanding shares as of January 1 (i.e. March 31)	<u>725</u>	<u>-</u>

The fair value of the new restricted employee shares granted in the current period was measured at the stock closing price on the grant date, August 8, 2025.

3. The share-based payment transactions granted by the Group on the grant date adopted the stock price on the grant date less the performance price to estimate the fair value of stock options; the relevant information is as follows:

<u>Type of arrangement</u>	<u>Grant date</u>	<u>Amount granted (thousand shares)</u>	<u>Stock price (NTD)</u>	<u>Exercise price</u>	<u>Expected volatility</u>	<u>Expected duration</u>	<u>Expected dividend</u>	<u>Risk-free interest rate</u>	<u>Fair value per unit (NTD)</u>
New restricted employee shares plan - A	2025.8.8	725	34.4	-	-	3 years	-	-	34.4

4. The expenses incurred from share-based payment transactions were as follows:

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
New restricted employee shares	<u>\$ 2,997</u>	<u>\$ -</u>

(17) Capital stock

1. On September 2, 2024, the Company acquired 100% of the equity of CCPC by 0.5 shares of the Company for every 1 share of CCPC. As of March 31, 2026, the Company's

authorized capital was \$5,000,000, and the actual number of common shares issued was 149,766 thousand shares (including 725 thousand new restricted employee shares), with a paid-in capital of \$1,497,656 and a par value of NTD 10 per share.

2. The Company's Board of Directors resolved on August 8, 2025 to issue 725 thousand new restricted employee shares. The base date for the issuance of new shares is August 8, 2025, and the subscription price per share is NTD 0. Except for restricted share transfer rights and the absence of dividend entitlement, the remaining rights and obligations of the common shares under the current issuance are equivalent to those of the issued common shares when employees fulfill the vesting conditions.
3. The beginning and ending outstanding shares for the three months ended March 31, 2026 and 2025 were as follows: (Unit: thousand shares)

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
January 1	146,141	148,514
Repurchase of treasury stock	-	(887)
March 31	<u>146,141</u>	<u>147,627</u>

4. The shares possessed by the associate of the Company by March 31, 2026, December 31, 2025 and March 31, 2025 are 21,027 thousand shares.
5. The Company's recovery of treasury stocks is as follows:

		<u>March 31, 2026</u>	
<u>Name of holding company</u>	<u>Reasons for recovery</u>	<u>Number of shares (thousand shares)</u>	<u>Book value</u>
Subsidiaries- Tairung Development Co., Ltd.	Long-term investment for transfer of shares to employees (Note)	414	\$ 28,054
The Company		3,211	118,577
		<u>December 31, 2025</u>	
<u>Name of holding company</u>	<u>Reasons for recovery</u>	<u>Number of shares (thousand shares)</u>	<u>Book value</u>
Subsidiaries- Tairung Development Co., Ltd.	Long-term investment for transfer of shares to employees (Note)	414	\$ 28,054
The Company		3,211	118,577
		<u>March 31, 2025</u>	
<u>Name of holding company</u>	<u>Reasons for recovery</u>	<u>Number of shares (thousand shares)</u>	<u>Book value</u>
Subsidiaries- Tairung Development Co., Ltd.	Long-term investment for transfer of shares to employees	414	\$ 28,054
The Company		1,000	38,351

Note: The Company's Board of Directors resolved to buy back treasury shares and transfer shares to employees on August 8, 2025, April 9, 2025 and December 26, 2024, respectively. The buyback period expired on October 9, 2025, June 9, 2025, and February 26, 2025. During the fourth quarter of 2025, 3,098 thousand shares were repurchased for a total of \$114,327.

- (1) According to the Securities and Exchange Act, the percentage of shares repurchased by the Company shall not exceed 10% of the total number of issued shares, and the total amount of the repurchase shall not exceed the sum of retained earnings plus the premium of issued shares and the realized capital reserve.
 - (2) The treasury stock held by the Company shall not be pledged and shall not be entitled to the rights of shareholders before transfer in accordance with the Securities and Exchange Act.
 - (3) According to the Securities and Exchange Act, the shares repurchased for transfer to employees should be transferred within five years from the date of repurchase. If the shares are not transferred after the expiration date, they should be deemed unissued shares of the Company and canceled for the change of registration.
6. On March 6, 2025, the Company's Board of Directors initially resolved to issue common shares or domestic convertible bonds (including secured or unsecured convertible bonds) through private placement. The actual number of shares to be issued or issuable upon conversion is proposed to be authorized by the shareholders' meeting to the Board of Directors, which shall determine the issuance based on capital market conditions, within a limit not exceeding 20% of the total number of issued shares (i.e., not exceeding 29,953,122 shares). On March 5, 2026, the Board of Directors resolved not to proceed with the aforementioned proposal and, at the same meeting, approved a new private placement of common shares or domestic convertible bonds (including secured or unsecured convertible bonds) under the same terms and conditions. As of May 5, 2026, the shareholders' meeting has not yet approved the private placement proposal for the current year.

(18) Capital surplus

		2026				
		Others				
		Treasury stock trade	New restricted employee shares	Difference between the actual acquisition or disposal of equity interest in a subsidiary and its book value	Changes in the ownership equity on a subsidiary	Changes in net equity of affiliated enterprises
January 1 (i.e. March 31)	Issuance premium	\$ 68,389	\$ 17,692	\$ 112	\$ 1,844	\$ 7,606
	\$ 5,812,204					

		2025				
		Others				
		Issuance premium	Treasury stock trade	Difference between the actual acquisition or disposal of equity interest in a subsidiary and its book value	Changes in the ownership equity on a subsidiary	
January 1 (i.e. March 31)		\$ 5,901,560	\$ 68,087	\$ 112	\$ 1,844	

1. According to the IFRS Q&A set and Letter (100) Ji-Mi-Zi No. 390 issued by the Accounting Research and Development Foundation dated October 26, 2018, the share exchange transaction between the CCPC on September 2, 2024 was deemed a reorganization under joint control. The Company is a continuation of the CCPC. The Company has reclassified the equity items related to the reorganization of assets and liabilities to the original amount, and the balance of the equity items exceeding the Company's newly issued capital stock and the aforementioned equity items to be deferred are adjusted to increase capital surplus.
2. According to the Company Act, capital reserves from premium income for issuing shares over face values and gift income, not only can offset losses, it can also issue new shares or cash according to the original shareholding when there is no accumulated losses in the company. According to the Securities Transactions Act and its related rules, where capital reserve is applied to supplement capital as above, the total amount cannot exceed 10% of the paid up capital. When the retained earnings of a company is not enough to offset capital losses, the capital reserves cannot be applied.

(19) Retained earnings

1. According to the Articles of Incorporation of the Company, the dividend policy is planned in consideration of the future capital requirements and long-term financial arrangement and to meet the requirement of cash inflow by the shareholders, if there are any earnings in the general annual report, the tax should be paid firstly and make up for the previous annual losses, then allocate 10% as legal reserve and special reserve based on the regulations, if any earnings are still available, accumulated with the undistributed earnings from the previous year as profit available for distribution, to reserve according to the sales with discretion, and allocate bonus to shareholders, of which the cash dividends shall not be less than 50% of the shareholder bonus and if the cash dividend is less than NTD 0.1, the stock dividends will be issued instead.
2. Legal earnings reserves can only be applied to offset company losses or issue new shares or cash according to the original shareholding ratio, and nothing else. When it is applied to new share or cash issues, the reserve shall exceed 25% of the paid-up capital.
3. (1) In accordance with the regulations, the Company shall set aside special reserve from the debit balance of other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings.
(2) As stated in Note 6(18), the Company is a continuation of CCPC. When it first adopted IFRSs, the Financial Supervisory Commission (FSC) issued Jin-Guan-Zheng-FA-Zi No. 1010012865. On April 6, 2012, which the Company adopts hereafter to implement, the disposal or reclassification of relevant assets is subject to a reversal based on the proportion of the special earned surplus as initially recognized. If the previously stated relevant assets are investment real properties, reversal with disposal or reclassification should be applied for those classified as land. For those assets other than land, the reversal should occur gradually while they are in use.
4. On May 27, 2025, the Company's shareholders meetings' resolved to distribute cash of NTD 0.6 per share from capital surplus, totaling \$89,356.

5. On March 5, 2026, the Company's Board of Directors proposed the 2025 earnings distribution proposal, and the 2024 earnings distribution proposal was approved by the shareholders' meeting on May 27, 2025 as follows:

	2025		2024	
	Amount	Dividends per share (\$)	Amount	Dividends per share (\$)
Legal reserve	\$ 24,361		\$ 11,362	
Special reserve	-		33,809	
Cash dividends	145,830	\$ 1.0	59,571	\$ 0.4
	<u>\$ 170,191</u>		<u>\$ 104,742</u>	

As of May 5, 2026, the shareholders' meeting has not yet resolved the abovementioned earnings distribution proposal for 2025.

The relevant information about the disposition of earnings as above stated which decided by the shareholders can be inquired on the “Market observation post system” of Taiwan Stock Exchange Corporation.

(20) Other equity

	2026			
	Unrealized loss of profit valuation	Foreign-currency translations	Unearned Employee Compensation	Total
January 1	(\$ 71,642)	(\$ 82,116)	(\$ 20,083)	(\$ 173,841)
Evaluation adjustment:				
- Group	(17,802)	-	-	(17,802)
- Affiliated enterprises	569	-	-	569
- Valuation adjustment changes to earnings	2,849	-	-	2,849
Foreign currency translation differences:				
- Group	-	37,594	-	37,594
- Tax of the group	-	(7,518)	-	(7,518)
- Affiliated enterprises	-	180	-	180
Cost of share-based remuneration	-	-	2,997	2,997
March 31	<u>(\$ 86,026)</u>	<u>(\$ 51,860)</u>	<u>(\$ 17,086)</u>	<u>(\$ 154,972)</u>

	2025		
	Unrealized loss of profit valuation	Foreign-currency translations	Total
January 1	(\$ 137,597)	(\$ 85,170)	(\$ 222,767)
Evaluation adjustment:			
- Group	(3,238)	-	(3,238)
- Valuation adjustment changes to retained earnings	61,981	-	61,981
Foreign currency translation differences:			
- Group	-	25,991	25,991
- Tax of the group	-	(5,198)	(5,198)
- Affiliated enterprises	-	45	45
March 31	<u>(\$ 78,854)</u>	<u>(\$ 64,332)</u>	<u>(\$ 143,186)</u>

(21) Operating revenues

	January 1 to March 31, 2026	January 1 to March 31, 2025
Revenue from sales contract	\$ 2,183,198	\$ 2,216,071
Revenue from labor service contract	45,659	39,557
	<u>\$ 2,228,857</u>	<u>\$ 2,255,628</u>

1. Subdivision of the revenue from contracts with customers

The Group generates revenue by transferring products and labor services to customers either at a point in time or over time. Revenue details are listed as follows:

January 1 to March 31, 2026	Taiwan	China	Other regions	Total
Sales contract	\$ 1,705,660	\$ 400,626	\$ 76,912	\$ 2,183,198
Labor service contract	45,659	-	-	45,659
	<u>\$ 1,751,319</u>	<u>\$ 400,626</u>	<u>\$ 76,912</u>	<u>\$ 2,228,857</u>

January 1 to March 31, 2025	Taiwan	China	Other regions	Total
Sales contract	\$ 1,638,523	\$ 485,918	\$ 91,630	\$ 2,216,071
Labor service contract	39,557	-	-	39,557
	<u>\$ 1,678,080</u>	<u>\$ 485,918</u>	<u>\$ 91,630</u>	<u>\$ 2,255,628</u>

2. Contractual liability

The contractual liability relating to the contract with a customer which The Group recognizes is as follows:

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Contractual liability- Sales contract of medicine	<u>\$ 68,640</u>	<u>\$ 39,937</u>	<u>\$ 36,664</u>

3. Current income recognized from beginning lease liability in for the three months ended March 31, 2026 and 2025 were \$10,224 and \$11,575, respectively.

4. The refund liability which The Group recognized for some goods with right of return is as follows:

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
January 1	\$ 58,706	\$ 94,638
Decrease	(20,881)	(11,760)
Used in the current period	<u>(15,979)</u>	<u>(13,766)</u>
March 31	<u>\$ 21,846</u>	<u>\$ 69,112</u>

(22) Interest income

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
Interest from bank deposits	\$ 331	\$ 65
The interest revenue of financial assets at amortized cost	605	699
Other interest incomes	<u>1,343</u>	<u>1,553</u>
	<u>\$ 2,279</u>	<u>\$ 2,317</u>

(23) Other income

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
Rent revenue	\$ 2,098	\$ 2,042
Grant income	1,607	1,991
Other Revenue- other	<u>6,501</u>	<u>1,138</u>
	<u>\$ 10,206</u>	<u>\$ 5,171</u>

(24) Other profits and losses

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
Gain in disposal of property, plant, and equipment	\$ -	\$ 22
Net foreign exchange profit (loss)	(637)	1,782
Depreciation of investment property	(839)	(833)
Others	<u>791</u>	<u>-</u>
	<u>(\$ 685)</u>	<u>\$ 971</u>

(25) Employees' welfare and depreciation, amortization expenses

Functionality Characteristics	<u>January 1 to March 31, 2026</u>		
	<u>Allocated as operating cost</u>	<u>Employee expenses</u>	<u>Total</u>
Employee benefits expenses			
Salaries and wages	\$ 171,547	\$ 310,745	\$ 482,292
Cost of share-based remuneration	362	2,635	2,997
Labor insurance and national health insurance	18,159	25,385	43,544
Pension expenses	10,036	16,616	26,652
Other employee benefits expenses	11,598	22,352	33,950
Depreciation expenses	57,624	28,412	86,036
Amortization expenses	788	1,388	2,176

Functionality Characteristics	<u>January 1 to March 31, 2025</u>		
	<u>Allocated as operating cost</u>	<u>Employee expenses</u>	<u>Total</u>
Employee benefits expenses			
Salaries and wages	\$ 159,874	\$ 286,579	\$ 446,453
Labor insurance and national health insurance	17,614	24,214	41,828
Pension expenses	10,346	16,115	26,461
Other employee benefits expenses	11,595	14,656	26,251
Depreciation expenses	54,229	28,871	83,100
Amortization expenses	68	2,656	2,724

1. According to the Articles of Incorporation as amended by the Company's shareholders'

meeting on May 27, 2025, if a balance remains after deducting accumulated losses from the current year's profit, 1% to 15% of the balance shall be appropriated as remuneration to employees, and no more than 3% as remuneration to directors. Of the employee remuneration, no less than 10% shall be allocated to entry-level employees.

2. (1) The estimated amount of employee remuneration for the three months ended March 31, 2026 and 2025 were \$2,188 and \$3,900, respectively; the estimated amount of director remuneration were \$2,000 and \$1,750, respectively. The aforementioned amount was recorded in the account of salary expense.
- (2) The estimated recognition for the three months ended March 31, 2026 is based on the profitability of the year, of which 1.09% for employee bonus and 0.99% for the bonus of the members of the board. The above stated employee bonus is distributed in cash.
- (3) Per the Board of Directors' resolution, the estimated remuneration to employees for 2025 was \$17,003 and the estimated remuneration to directors was \$7,000, both of which are consistent with the amounts recognized in the financial statements for 2025. The remuneration to employees and directors/supervisors for 2025 had not been paid out.
3. Information on the employee and remuneration for directors as approved by the board of directors can be found on the Market Observation Post System.

(26) Financial costs

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
Interest expenses:		
Bank loan	\$ 13,389	\$ 14,092
Interest expense on the lease liability	1,732	1,711
Interest expense on decommissioning liabilities	17	17
Other financial expenses	<u>5</u>	<u>5</u>
	<u>\$ 15,143</u>	<u>\$ 15,825</u>

(27) Income tax

1. Income tax expense

(1) Components of income tax expense:

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
Current income tax:		
Current income tax	\$ 25,721	\$ 31,718
Underestimated (overestimated) income tax in prior periods	<u>19</u>	<u>3,671</u>
Total Current income tax	<u>25,740</u>	<u>35,389</u>
Deferred income tax:		
Origin and reversal of temporary differences	23,054	(5,975)
The influence of change in tax rate	<u>48</u>	<u>-</u>
Total deferred income tax	<u>23,102</u>	<u>(5,975)</u>
Income tax expenses	<u>\$ 48,842</u>	<u>\$ 29,414</u>

(2) Income tax amounts relating to other comprehensive profit and loss:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Exchange differences in overseas operating institutions	\$ <u>7,518</u>	\$ <u>5,198</u>

2. As the Company was established on September 2, 2024, no profit-seeking enterprise income tax had been approved. The filings of profit-seeking enterprise business income tax returns of the remaining domestic subsidiaries of the Group had been certified by the tax authority up to 2023.

(28) Earnings per share

	January 1 to March 31, 2026		
	After-tax amount	Weighted average outstanding shares (thousand shares)	Earnings per share (NTD)
<u>Basic earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ <u>195,893</u>	<u>124,389</u>	\$ <u>1.57</u>
<u>Diluted earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 195,893	124,389	
The impact of potential diluting common stock:			
remuneration to employees	-	428	
Restricted employee shares	-	<u>36</u>	
Net income attributable to the parent company and impact of potential common stock	\$ <u>195,893</u>	<u>124,853</u>	\$ <u>1.57</u>

	January 1 to March 31, 2025		
	After-tax amount	Weighted average outstanding shares (thousand shares)	Earnings per share (NTD)
<u>Basic earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 117,994	126,945	\$ 0.93
<u>Diluted earnings per share</u>			
Net income attributable to the parent company's common stock shareholders	\$ 117,994	126,945	
The impact of potential diluting common stock: remuneration to employees	-	209	
Net income attributable to the parent company and impact of potential common stock	\$ 117,994	127,154	\$ 0.93

(29) Supplementary information about the cash flows
Investing activities partially funded with cash:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Purchase of property, plant, and equipment	\$ 33,985	\$ 26,543
Less: Prepayments for equipment at the beginning of the period (recognized as other non-current assets)	(82,671)	(34,071)
Add: Outstanding payments for equipment at the end of the period (recognized in other non-current liabilities)	89,265	34,904
Add: Construction and equipment payable at the beginning of the period (recognized in other payables)	34,776	38,688
Less: Construction and equipment payable at the Ending of the period (recognized in other payables)	(20,540)	(24,482)
Add: Long-term payables for construction and prepayments for business at the beginning of the period (recognized in other non-current liabilities)	7,160	8,299
Less: Long-term payables for construction and prepayments for business at the end of the period (recognized in other non-current liabilities)	(6,672)	(8,299)
Cash Paid for the Period	\$ 55,303	\$ 41,582

(30) Changes in liability from financial activities.

	Shot-term borrowings	Short-term notes payable	Long-term borrowings	Lease liabilities	Deposits received	Total liabilities from financial activities.
January 1, 2026	\$ 2,007,743	\$ 380,000	\$ 240,800	\$ 357,555	\$ 19,211	\$ 3,005,309
Borrowing/ Increase	535,042	30,000	-	3,036	-	568,078
Repayment/ Payment	(485,000)	-	(10,400)	(13,562)	(1,737)	(510,699)
Changes from non-cash items	-	-	-	(34)	-	(34)
Changes in exchange rate	-	-	-	945	565	1,510
March 31, 2026	<u>\$ 2,057,785</u>	<u>\$ 410,000</u>	<u>\$ 230,400</u>	<u>\$ 347,940</u>	<u>\$ 18,039</u>	<u>\$ 3,064,164</u>

	Shot-term borrowings	Short-term notes payable	Long-term borrowings	Lease liabilities	Deposits received	Total liabilities from financial activities.
January 1, 2025	\$ 1,381,789	\$ 88,992	\$ 1,315,500	\$ 354,275	\$ 28,575	\$ 3,169,131
Borrowing/ Increase	587,395	527,008	-	5,454	-	1,119,857
Repayment/ Payment	(192,000)	(109,000)	(826,300)	(12,369)	(1,559)	(1,141,228)
Changes in exchange rate	-	-	-	707	585	1,292
March 31, 2025	<u>\$ 1,777,184</u>	<u>\$ 507,000</u>	<u>\$ 489,200</u>	<u>\$ 348,067</u>	<u>\$ 27,601</u>	<u>\$ 3,149,052</u>

7. Related party transactions

(1) Name and relationship of related parties

Name	Relationship with the Group
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB)	Associate of The Group
Sino-Japan Chemical Co., Ltd. (Sino-Japan Chemical)	Associate of The Group
PHERMPEP CO., LTD. (PHERMPEP)	Associate of The Group
Wuxi Jirui Medical Technology Co., Ltd. (Wuxi Jirui)	Associate of The Group
HU-YU CO., LTD (HU-YU)	The individual controlled by major management team of The Group
Markart Enterprise Co., Ltd. (Markart)	The individual controlled by major management team of The Group
Sela Holdings Inc.	The individual controlled by major management team of The Group
Cafe Warm Up Occupational Therapy Center (Cafe Warm Up)	Other related parties
Wang Hsien, I-Chen	Major management team of The Group

(2) Major transactions with related parties

1. Operating revenues

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
Merchandising:		
One of the individuals controlled by the major management team		
- HU-YU	\$ 17,788	\$ 45,783
- Markart	-	2
Affiliated enterprises	<u>63</u>	<u>23</u>
	<u>\$ 17,851</u>	<u>\$ 45,808</u>

(1) The transaction price for the joint replacement products that CCPC sells is made by the individual controlled by the major management team based on the import cost plus 4%. Due to the industry peculiarities, the payment is Net 240 days which is longer than the general transactions.

(2) The payment term of The Group for general customers is 120 days to 180 days. Except for the previous statement, the payment term and transaction price for related party is relevant to customers at the same level, however, part of the payment is still being delayed.

2. Purchases

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
Purchase of goods:		
Affiliated enterprises	<u>\$ 5,393</u>	<u>\$ 15,544</u>

The purchase from The Group to the related party is based on the general commercial conditions, and the payment is 3~4 months with remittance after purchasing. However, part of payment is still delayed.

3. Accounts receivable and notes

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Accounts receivable and notes:			
The individual controlled by major management team- HU-YU	\$ 167,908	\$ 186,572	\$ 125,975
Affiliated enterprises	<u>11</u>	<u>15</u>	<u>10</u>
	167,919	186,587	125,985
Less: Allowance for losses	<u>(25,186)</u>	<u>(28,676)</u>	<u>(18,896)</u>
Total	<u>\$ 142,733</u>	<u>\$ 157,911</u>	<u>\$ 107,089</u>

- (1) In general, the Company grants payment periods ranging from 120 days to 180 days for general customers, and 240 days for individual entities controlled by the key management. For financial instruments dated beyond the aforementioned payment period, the Board resolved to treat as loans, and has been recognized as “other receivables -related parties”. These loans are accompanied by the letter of surety issued by the Chairman of the Company. For additional information, refer to Note 7 (2) 5 (1), “entities controlled by key management”.
- (2) Account and note receivables as of March 31, 2026, December 31 and March 31, 2025 were from customer contracts. Account receivables and the associated allowed made stood at \$244,451 and \$36,663, respectively, on January 1, 2025.
- (3) The exposure amounts of the maximum credit risk which can represent the accounts receivable and bill receivable of the Group's related parties without considering the possessed collateral or other credit enhancement condition on March 31, 2026, December 31 and March 31, 2025 are its book amount .
- (4) The aging analysis of accounts receivable and bill receivable is as follows:

	March 31, 2026		December 31, 2025	
	Accounts receivable	Notes receivable	Accounts receivable	Notes receivable
Not-overdue	\$ 32,271	\$ 135,648	\$ 48,422	\$ 109,932
Overdue within 1-90 days	-	-	-	28,233
	<u>\$ 32,271</u>	<u>\$ 135,648</u>	<u>\$ 48,422</u>	<u>\$ 138,165</u>
			March 31, 2025	
			Accounts receivable	Notes receivable
Not-overdue			<u>\$ 46,114</u>	<u>\$ 79,871</u>

4. Accounts payable

	March 31, 2026	December 31, 2025	March 31, 2025
Accounts payable:			
Affiliated enterprises	<u>\$ 8,744</u>	<u>\$ 9,297</u>	<u>\$ 22,728</u>

The purchase from The Group to the related party is based on the general commercial conditions, and the payment is 3~4 months with remittance after purchasing. However, part of payment is still delayed.

5. Other receivables

(1) A. Related party of the loan funds

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
The individual controlled by major management team- HU-YU			
Overdue accounts receivable and notes receivable transferred to other receivables	\$ 150,580	\$ 129,356	\$ 158,286
Financing amount receivable	<u>93,000</u>	<u>91,500</u>	<u>129,000</u>
	243,580	220,856	287,286
Less: Allowance for losses	<u>(34,587)</u>	<u>(31,882)</u>	<u>(23,743)</u>
	<u>\$ 208,993</u>	<u>\$ 188,974</u>	<u>\$ 263,543</u>

B. Interest income

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
The individual controlled by major management team- HU-YU	<u>\$ 1,220</u>	<u>\$ 1,328</u>

(2) Interest receivable, rent receivable, labor service and collection and payment transfer.

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
The individual controlled by major management team- HU-YU	\$ 400	\$ 378	\$ 424
Affiliated enterprises	<u>3,400</u>	<u>7</u>	<u>8</u>
	<u>\$ 3,800</u>	<u>\$ 385</u>	<u>\$ 432</u>

6. Acquisition of financial assets

For the three months ended March 31, 2026: none.

	<u>Account titles in book</u>	<u>Number of shares</u>	<u>Object of transaction</u>	<u>January 1 to March 31, 2025 Prices of acquirements</u>
Affiliate -Wuxi Jirui Medical Technology Co., Ltd.	Investment under the equity method		Wuxi Jirui Medical Technology Co., Ltd.	<u>\$ 463</u>

7. Provide the endorsement guarantee status of the related party

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
The individual controlled by major management team- HU-YU	<u>\$ 223,600</u>	<u>\$ 250,600</u>	<u>\$ 237,600</u>

Of the balance of endorsement and guarantee of the Group as of March 31, 2026, the Group actually undertook endorsement and guarantee in favor of Hu Yu Co., Ltd. At \$72,300, given the renewal of contract and the previous reporting to the Board for the approval of the amount of \$151,300.

(3) Remuneration to key management

	<u>January 1 to March 31, 2026</u>	<u>January 1 to March 31, 2025</u>
Short-term employee benefits	\$ 23,227	\$ 26,081
Retirement benefits	253	249
Share-based payment	<u>1,944</u>	<u>-</u>
	<u>\$ 25,424</u>	<u>\$ 26,330</u>

8. Pledged assets

The assets of the Group are offered as collateral as follows:

<u>Asset Item</u>	<u>Book Value</u>			<u>Purpose of guarantee</u>
	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>	
Land, buildings and structures (recognized in property, plant, and equipment and investment property)	\$ 2,615,568	\$ 2,635,692	\$ 2,691,640	Long-term and short-term loan, purchase...etc.
Refundable deposits (recognized in other non-current assets)	<u>78,259</u>	<u>75,600</u>	<u>58,351</u>	
	<u>\$ 2,693,827</u>	<u>\$ 2,711,292</u>	<u>\$ 2,749,991</u>	Leasing security deposits, bid bonds, and court deposits

9. Significant contingent liabilities and unrecognized contractual commitments

(1) Contingencies

1. In February 2025, the Company received a letter from the Securities and Futures Investors Protection Center, claiming that the subsidiary CCPC should compensate the counterparty, a claim that the Supreme Court has enforced. The Company is currently in the process of negotiating the repayment process with the counterparty. The Company obtained the affidavit from the counterparty in February 2026, and the counterparty promised that it would not dispose of the stocks of Cenra or Cenra API Solutions that it held in its name by

any means without prior written consent from the Company.

2. In May 2025, SCCPC, a subsidiary of the Group, had a dispute over a technical entrustment development contract with Nanjing Healthnice Pharmaceutical Technology Co., Ltd. ("Nanjing Healthnice"). To develop roxatidine acetate hydrochloride for injection (with a specification of 75 mg), the Company entrusted Nanjing Healthnice with the development of the project, the applications for approval documents for the production permit, commercial mass production, and other technical services. With the Company as the defendant, Nanjing Healthnice required the Company to pay a contract progress payment of \$2,919 and overdue interest of \$268, and to continue fulfilling the contract's implementation items. In July 2025, the Company filed a counterclaim to require Nanjing Healthnice, the defendant, to cancel the contract and return the technical service fee of \$9,749, liquidated damages of \$523, and compensation for material costs of \$3,743. On February 14, 2026, the Nanjing Jiangbei New Area People's Court, Jiangsu Province ruled that the Company shall pay interest on overdue payment of \$18, while Nanjing Healthnice shall return the technical service fee and compensate for material loss totaling \$6,282. The other claims of both parties were dismissed. SCCPC appealed in March 2026, and the case is currently being heard by the Nanjing Jiangbei New Area People's Court, Jiangsu Province in the second instance proceedings.

(2) Commitments

1. The Company has signed contracts for the purchase of machine and equipment, construction work for the plant, intangible assets and consulting service with outstanding payment amounting to \$286,429, \$324,471 and \$139,298 as of March 31, 2026, March 31 and December 31, 2025, respectively. In the contract of consultation services, part of the performance expenses are paid according to the plan benefits.
2. The unused L/C balance as of March 31, 2026, March 31 and December 31, 2025 were \$21,327, \$13,360 and \$19,749 respectively.
3. The amounts issued as of March 31, 2026, December 31 and March 31, 2025 were \$3,746,000, \$4,041,410, and \$3,923,200, respectively.

10. Significant disaster loss

No such event

11. Significant subsequent events

The Company's Board of Directors resolved on May 5, 2026 to buy back treasury stocks for transfer to employees. It is estimated that 1,000 thousand shares will be bought back, with a price range of \$24 to \$42 per share. However, the shares may be continuously bought back at a price lower than the range price.

12. Others

(1) Capital management

The Group's capital risk management objectives are to ensure that the Group is capable of continuing operations, to maintain the most appropriate capital structure in order to reduce cost of capital and to maximize returns for shareholders. The Group may make adjustments to dividends paid to shareholders, refund capital to shareholders, issue new shares or sell assets to reduce the level of debts in order to maintain or adjust the Group's capital structure. The Group uses the debt-to-equity ratio to monitor its capital. The ratio is calculated by dividing net debts by total capital. Net debts are calculated as total debts (including "current and non-current borrowings" presented in the consolidated balance sheet) less cash and cash equivalents. Total capital is calculated as "equity" presented in the consolidated balance sheet

plus net debts.

The strategy of the Group in 2026 is the same as that in 2025, which is dedicated to maintain the debt-to-capital ratio to 40% below. The debt-to-capital ratio of The Group in March 31, 2026, March 31 and December 31, 2025 were as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Total loan amount	\$ 2,698,185	\$ 2,628,543	\$ 2,773,384
Less: Cash and cash equivalent	(900,139)	(729,497)	(745,094)
Net debt	1,798,046	1,899,046	2,028,290
Total equity	7,820,641	7,611,632	7,651,065
Total capital	\$ 9,618,687	\$ 9,510,678	\$ 9,679,355
Liability/assets ratio	19%	20%	21%

(2) Financial instruments

1. Categories of financial instruments

	March 31, 2026	December 31, 2025	March 31, 2025
<u>Financial assets</u>			
Financial assets at fair value through other comprehensive profit or loss			
Select the designated equity instrument investment.	\$ 204,610	\$ 166,496	\$ 188,594
Financial assets measured at the amortized cost			
Cash and cash equivalents	900,139	729,497	745,094
Financial assets measured at the amortized cost	139,513	134,866	98,168
Notes receivable	408,017	450,915	417,642
Accounts receivable	1,525,475	1,507,307	1,532,787
Other receivables	225,223	205,835	285,325
Finance lease receivables (including current and non-current)	3,978	4,139	-
Refundable deposits (recognized in other non-current assets)	78,259	75,600	58,351
	<u>\$ 3,485,214</u>	<u>\$ 3,274,655</u>	<u>\$ 3,325,961</u>

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
<u>Financial liabilities</u>			
Financial liability measured at the amortized cost			
Shot-term borrowings	\$ 2,057,785	\$ 2,007,743	\$ 1,777,184
Short-term notes payable	410,000	380,000	507,000
Payable notes	796	807	453
Accounts payable	759,189	750,296	765,033
Other payables	555,593	720,125	645,765
Deposits received	18,039	19,211	27,601
Long-term payables (recognized in other non-current liabilities)	6,672	7,160	8,299
The long-term loan (including the expiration of one year or an operating cycle)			
	<u>230,400</u>	<u>240,800</u>	<u>489,200</u>
	<u>\$ 4,038,474</u>	<u>\$ 4,126,142</u>	<u>\$ 4,220,535</u>
Lease liability (including current and non-current)	<u>\$ 347,940</u>	<u>\$ 357,555</u>	<u>\$ 348,067</u>

2. Risk management policies

- (1) The daily operation of The Group is affected by multiple financial risks, which include the market risk (currency risk, interest rate risk and price risk), credit risk and liquidity risk. The overall risk management policy of The Group is to focus on the unpredictable matters of the financial market and seek for the method to decrease the potential adverse impact on the financial situation and financial performance of The Group.
- (2) The risk management is executed by the financial center of The Group according to the policies approved by the board of directors. The financial center of the group works close with the operation unit of The Group to identify, evaluate and avoid risk. The board of director also sets the written principle for the overall management risk and provides a written policy for specific scope and matters, ex. currency risk, interest rate risk, credit risk, use of derivative and non-derivative financial instruments as well as the investment of the remaining liquidity.

3. Nature and degree of the significant financial risk.

(1) Market Risk

Exchange rate risk

- A. The operation of the Group is transnational, which suffers from the currency occurred by multiple currencies and the majority is USD, RMB and JPY. The relevant currency risk comes from the future commercial deals, recognized

assets and liability as well as the net investment of the foreign operation.

- B. The business of the Group involves several non-functional currencies (the functional currency of the Company and some subsidiaries is NTD, while that of some subsidiaries are RMB), and therefore are affected by the exchange rate fluctuation, the information about the currency with significant exchange rate fluctuation is as follows:

				March 31, 2026		
				Foreign currency (NTD thousand)	Exchange rate	Book value (NTD)
(Foreign currency: Functional currency)						
<u>Financial assets</u>						
<u>Monetary items</u>						
JPY: NTD	\$	153,568		0.2005	\$	30,790
USD: NTD		963		32.00		30,816
JPY: RMB		1,008		0.0400		172
USD:RMB		544		6.91		16,062
<u>Financial liabilities</u>						
<u>Monetary items</u>						
JPY: NTD	\$	30,430		0.2005	\$	6,101
USD: NTD		2,793		32.00		89,376
				December 31, 2025		
				Foreign currency (NTD thousand)	Exchange rate	Book value (NTD)
(Foreign currency: Functional currency)						
<u>Financial assets</u>						
<u>Monetary items</u>						
JPY: NTD	\$	164,892		0.2007	\$	33,094
USD: NTD		1,228		31.40		38,559
JPY: RMB		13,340		0.0447		2,548
USD:RMB		827		6.99		24,701
<u>Financial liabilities</u>						
<u>Monetary items</u>						
JPY: NTD	\$	52,685		0.2007	\$	10,574
USD: NTD		3,958		31.40		124,281

March 31, 2025			
	Foreign currency (NTD thousand)	Exchange rate	Book value (NTD)
(Foreign currency: Functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
JPY: NTD	\$ 314,411	0.2232	\$ 70,177
USD: NTD	527	33.20	17,496
JPY: RMB	18,396	0.0488	4,106
USD:RMB	2,350	7.26	78,037
<u>Financial liabilities</u>			
<u>Monetary items</u>			
JPY: NTD	\$ 83,902	0.2232	\$ 18,727
USD: NTD	1,760	33.20	58,432

C. The amounts of the unrealized gains and losses with significant exchange rate fluctuation for the currency of the Group recognized for the three months ended March 31, 2026 and 2025 were summed amount respectively as \$(1,194) and \$ 3,718.

D. The analysis of foreign exchange risk affected by significant exchange rate fluctuation for The Group is as follows.

January 1 to March 31, 2026			
Sensitivity analysis			
	Magnitude changes	Influence of profit and loss	The impact of other comprehensive profit or loss
(Foreign currency: Functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
JPY: NTD	1%	\$ 308	\$ -
USD: NTD	10%	3,082	-
JPY: RMB	1%	2	-
USD:RMB	10%	1,606	-
<u>Financial liabilities</u>			
<u>Monetary items</u>			
JPY: NTD	1%	\$ 61	\$ -
USD: NTD	10%	8,938	-

January 1 to March 31, 2025

	Sensitivity analysis		
	Magnitude changes	Influence of profit and loss	The impact of other comprehensive profit or loss
(Foreign currency: Functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
JPY: NTD	1%	\$ 702	\$ -
USD: NTD	10%	1,750	-
JPY: RMB	1%	41	-
USD:RMB	10%	7,804	-
<u>Financial liabilities</u>			
<u>Monetary items</u>			
JPY: NTD	1%	\$ 187	\$ -
USD: NTD	1%	584	-

Price risk

- A. The equity instrument exposed to price risk of The Group means all financial assets listed in the account at fair value through other comprehensive income. To manage the price risk for the investment of equity instrument, The Group will break down the investment portfolio which is followed by the limited amount set by The Group.
- B. The Group mainly invests in the domestic listed and unlisted equity instrument, the price of such equity instrument will be affected by the uncertainty of the future value of that investment object. If the price of that equity instrument rises or drops 1%, and all other elements remain the same, the losses or profits of the equity investment classified by fair value through other comprehensive income and financial assets at amortized cost for the three months ended March 31, 2026 and 2025 are, respectively, decreased or increased for \$2,046 and \$1,886.

Cash flows and the interest risk of fair value

- A. The interest risk of The Group comes from the long-term loan, short-term loan and short-term bills receivable. The Group suffers from the interest rate risk of the cash flows based on the loan issued according to floating rate, part of the risk is being offset with the cash and cash equivalents based on the floating rate. The Group suffers from the interest rate risk of the fair value with the loan issued based on the fixed rate. The loan of The Group is mainly with floating rate. The loan amount of the Group for the three months ended March 31, 2026 and 2025 were based on the floating rate in NTD and US dollars.
- B. For the three months ended March 31, 2026 and 2025, if the change in loan interest rates is 0.1%, and all other elements are remained the same, net incomes for the three months ended March 31, 2026 and 2025 will respectively decreases \$2,159 and \$2,219 mainly because of the increase or decrease of the interest for the loan of floating interest.

(2) Credit Risk

- A. The credit risk of the Group is the risk deriving from the financial loss caused by the failure of the customers or the counterparties of trade in financial instruments in performing their contractual obligations, and is mainly from the cash flow from the contracts of the account receivable that cannot be settled by the counterparties in accordance with the terms and conditions of payment, and is classified as cash flow from contracts of investment in debt instruments measured on the basis of amortized cost.
- B. The Group established credit risk management in view of a group. According to the credit policy specified internally, before setting the payment, delivery terms and conditions with the new customer, each operating individual in the group should manage and proceed with the credit risk analysis. The internal risk management is to evaluate the credit quality of the customer in consideration of the financial situation, previous experience and other factors. The limited amount of the individual risk is set by the board of director according to the internal or external rating and monitored with the use of the credit line regularly.
- C. The Group adopts IFRS 9 to provide the following assumption as the basis to judge if the credit risk of the financial instrument significantly increases since initial recognition:
- The credit risk of a financial asset is deemed to increase significantly since the recognition when a contract payment is 30 day past due.
- D. The Group adopts IFRS 9 to provide the assumption and based on actual receipt of payment previously that if the payment term in the contract exceeding 91-180 days, it will be considered as violation.
- E. The indicators used by the Group to determine the credit impairment of debt instrument investment are as follows:
- (A) The issuer is likely to enter into bankruptcy or other financial restructuring if it is experiencing major financial difficulties;
 - (B) The issuer makes the active market of the financial asset disappear due to financial difficulties;
 - (C) The issuer delays or fails to pay interest or principal;
 - (D) Changes in national or regional economic conditions that are related to the issuer's default.
- F. The Group classifies the accounts receivable of the customers according to the features of customer type with simplified method to prepare matrix and loss-rate approach as a base to estimate the expected credit loss.
- G. With the recourse process, The Group writes off the receivable amount of the financial assets which can't be expected reasonably, however, The Group will still proceed with the low process for recourse to reserve the equity of liability. By March 31, 2026, December 31 and March 31, 2025, the Group did not have the liability for creditor's with recourse write-off.
- H. The bill receivable and allowance account for change in loss of The Group is as follows:
- (1) The associates of the Group are with excellent credits; therefore, the expected loss rate is 0.2%, and the total carrying amounts of accounts receivable and other receivables as of March 31, 2026, December 31 and March 31, 2025 were NTD 11, NTD 15, NTD 10, and NTD 3,400, NTD 7,

and NTD 8 respectively, and no allowance for losses was provided.

- (2) The expected loss rate for the individual of the management team of the Group is 15%, and the total carrying amounts and allowances for loss on March 31, 2026, December 31 and March 31, 2025 are as follows:

Account and note receivables:	December 31,		
	March 31, 2026	2025	March 31, 2025
One of the individuals controlled by the major management team	\$ 167,908	\$ 186,572	\$ 125,975
Less: Allowance for losses	(25,186)	(28,676)	(18,896)
	<u>\$ 142,722</u>	<u>\$ 157,896</u>	<u>\$ 107,079</u>

Other receivables:	December 31,		
	March 31, 2026	2025	March 31, 2025
One of the individuals controlled by the major management team	\$ 243,980	\$ 221,234	\$ 287,710
Less: Allowance for losses	(34,587)	(31,882)	(23,743)
	<u>\$ 209,393</u>	<u>\$ 189,352</u>	<u>\$ 263,967</u>

- (3) The Group adjusts the loss rate established according to the historical and current information in a specific period of time in consideration of the completeness of vision, to estimate the bill receivable and allowance for loss. The prepared matrix of March 31, 2026, December 31 and March 31, 2025 are as follows:

	Not- overdue	1 to 90 days overdue	91 to 180 days overdue	Overdue exceeding 181 days	Total
<u>March 31, 2026</u>					
Expected rate of loss	0.01%~1.05 %	0.02%~10.08%	0.02%~100%	100%	
Total amount of the book value	\$ 1,851,960	\$ 66,004	\$ 2,716	\$ 2,948	\$1,923,628
Allowance for losses	3,284	3,255	1,548	2,948	11,035
<u>December 31, 2025</u>					
Expected rate of loss	0.01%~1.05 %	0.02%~10.08%	0.02%~100%	100%	
Total amount of the book value	\$ 1,906,819	\$ 42,328	\$ 4,320	\$ 3,207	\$1,956,674
Allowance for losses	4,155	2,135	2,254	3,207	11,751

<u>March 31, 2025</u>	<u>Not- overdue</u>	<u>1 to 90 days overdue</u>	<u>91 to 180 days overdue</u>	<u>Overdue exceeding 181 days</u>	<u>Total</u>
Expected rate of loss	0.02%~0.5%	0.02%~11.76%	0.02%~100%	100%	
Total amount of the book value	\$ 1,946,047	\$ 26,179	\$ 3,065	\$ 2,447	\$1,977,738
Allowance for losses	3,172	1,089	1,616	2,393	8,270

I. The change in allowance for loss table for bill receivable, accounts receivable and other accounts receivable by the Group are as follows:

	<u>2026</u>	
	<u>Note receivable and accounts receivable</u>	<u>Other receivables</u>
January 1	\$ 40,427	\$ 31,882
Impairment loss reversal	(1,780)	-
Reclassification	(2,705)	2,705
Foreign exchange impact amount	279	-
March 31	<u>\$ 36,221</u>	<u>\$ 34,587</u>

	<u>2025</u>	
	<u>Note receivable and accounts receivable</u>	<u>Other receivables</u>
January 1	\$ 48,816	\$ 23,901
Impairment loss reversal	(21,939)	-
Reclassification	158	(158)
Foreign exchange impact amount	131	-
March 31	<u>\$ 27,166</u>	<u>\$ 23,743</u>

J. The Group's credit risk rating information for assets measured at amortized cost is as follows:

	<u>March 31, 2026</u>			<u>Total</u>
	<u>By duration</u>		<u>Those with impaired credit risk</u>	
	<u>By 12 months</u>	<u>Those for whom credit risk has increased significantly</u>		
Financial assets measured at the amortized cost	<u>\$ 139,513</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 139,513</u>

	December 31, 2025				
	By duration				
	By 12 months	Those for whom credit risk has increased significantly		Those with impaired credit risk	Total
Financial assets measured at the amortized cost	\$ 134,866	\$ -	\$ -	\$ 134,866	

	March 31, 2025				
	By duration				
	By 12 months	Those for whom credit risk has increased significantly		Those with impaired credit risk	Total
Financial assets measured at the amortized cost	\$ 98,168	\$ -	\$ -	\$ 98,168	

(3) Liquidity risk

- A. The prediction of cash flows is executed by each operating unit in the group and summarized by the financial center of the group. The financial center of the group monitors the prediction for the liquidity requirement of the group, to ensure the capital is sufficient to support the operation requirements.
- B. The below table is the derivative financial liabilities of The Group, which is classified based on the due date. The derivative financial liabilities are analyzed according to the remaining period between the date of balance sheet to the expiry date of the contract. The amount of the cash flows in the contract disclosed by the following table is the undiscounted amount.

Non-derivative financial liabilities:

	Less than 3 months	3 months to 1 year	1 to 2 years	2 to 5 years	Over 5 year
March 31, 2026					
Shot-term borrowings	\$ 588,036	\$ 1,477,737	\$ -	\$ -	\$ -
Short-term notes payable	380,000	30,000	-	-	-
Notes payable	796	-	-	-	-
Accounts payable	577,180	182,009	-	-	-
Other payables	489,169	66,424	-	-	-
Lease liabilities	15,673	45,129	65,948	142,388	102,623

Long-term payables (recognized in other non-current liabilities)	-	-	1,953	4,719	-
Long-term borrowings	1,009	763	197,813	34,989	-
Deposits received	130	17,909	-	-	-
Financial commitment agreements	151,300	-	-	-	-
<u>Non-derivative financial liabilities:</u>					
December 31, 2025	Less than 3 months	3 months to 1 year	1 to 2 years	2 to 5 years	Over 5 year
Shot-term borrowings	\$ 502,238	\$ 1,511,234	\$ -	\$ -	\$ -
Short-term notes payable	380,000	-	-	-	-
Notes payable	807	-	-	-	-
Accounts payable	585,147	165,149	-	-	-
Other payables	678,954	41,171	-	-	-
Lease liabilities	15,423	45,323	65,737	145,739	110,994
Long-term payables (recognized in other non-current liabilities)	-	-	1,953	5,207	-
Long-term borrowings	1,051	180,921	22,122	41,881	-
Deposits received	130	18,363	718	-	-
Financial commitment agreements	178,300	-	-	-	-
<u>Non-derivative financial liabilities:</u>					
March 31, 2025	Less than 3 months	3 months to 1 year	1 to 2 years	2 to 5 years	Over 5 year
Shot-term borrowings	\$ 769,168	\$ 1,012,584	\$ -	\$ -	\$ -
Short-term notes payable	507,000	-	-	-	-
Notes payable	453	-	-	-	-
Accounts payable	692,083	72,950	-	-	-
Other payables	600,956	44,809	-	-	-
Lease liabilities	14,092	41,282	52,242	127,932	140,950
Long-term payables (recognized in other non-current liabilities)	-	-	1,953	5,858	488
Long-term borrowings	8,249	21,952	434,934	34,049	-
Deposits received	-	26,269	1,332	-	-
Financial commitment agreements	158,300	-	-	-	-

(3) Fair value information

1. For the Group's financial assets and liabilities not measured at fair value, including cash and cash equivalents, financial assets measured at amortized cost — non-current, bills receivable, accounts receivable, other receivables, finance lease receivables (including current and non-current), refundable deposits, short-term borrowings, short-term bills payable, notes payable, accounts payable, other payables, deposits received, long-term payables, long-term borrowings (including long-term borrowings due within one year or within the Group's operating cycle) and lease liabilities (including current and non-current), the amount is a reasonable approximation of fair value. Please refer to Note 12 (2) 1. for details.

2. The valuation technique for measuring the fair value of financial and non-financial instruments is defined as follows:

Level 1: The quotation (unadjusted) of the same assets or liabilities that can be acquired by the company in an active market on the measurement date. An active market refers to the market with sufficient frequency and quantity of the assets or liabilities transactions took place in order to provide market pricing information constantly. The fair value of the stock investment for the listed stock invested by The Group is all included.

Level 2: It refers to the directly or indirectly observable input value of asset or liability, except for those quotations included in Level 1. The fair value of structured deposits invested by the Group and embedded in derivatives is within this level.

Level 3: The unobservable inputs of assets or liabilities.

3. The fair values of investment property calculated by the cost method as of March 31, 2026, December 31 and March 31, 2025 were \$216,085, \$ 208,108 and \$192,382, respectively; these fair values were estimated based on market prices of similar properties in the vicinity.

4. The Group's financial and non-financial instruments measured at fair value are classified by the nature of assets and liabilities, characteristics and risks, and fair value as follows:

- (1) The relevant information about the classification of the nature for the assets and liabilities of the Group is as follows:

<u>March 31, 2026</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Repeatable fair value</u>				
Investment of equity instruments at fair value through other comprehensive income	<u>\$ 108,276</u>	<u>\$ -</u>	<u>\$ 96,334</u>	<u>\$ 204,610</u>
<u>December 31, 2025</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Repeatable fair value</u>				
Investment of equity instruments at fair value through other comprehensive income	<u>\$ 63,792</u>	<u>\$ -</u>	<u>\$ 102,704</u>	<u>\$ 166,496</u>

March 31, 2025	Level 1	Level 2	Level 3	Total
Assets				
<u>Repeatable fair value</u>				
Investment of equity instruments at fair value through other comprehensive income	\$ 96,529	\$ -	\$ 92,065	\$ 188,594

(2) The methods and assumptions used by the Group to measure fair value are described as follows:

A. The Group adopts the market quotation as the input value for the fair value (which is the first class), the classification according to the feature of the tool is as follows:

	<u>Listed (OTC) and emerging stocks</u>
Market quotation	Closing price

B. Besides the financial instrument of the active market as stated above, the fair value of other financial instrument is obtained by evaluation technique or reference of the counter party.

C. While evaluating the financial instrument which is non-standardized and with low complexity, The Group adopts the evaluation technique which is comprehensively used by the market participants. The parameter used for the valuation model of such financial instrument is usually the observable information of the market.

D. What the valuation model comes out is the estimated value, and the evaluation technique can't reflect all relating factors of the financial instrument and non-financial instrument of The Group. Therefore, the estimated value of the valuation model will be adjusted based on the additional parameter properly, such as the model risk or liquidity risk...etc. According to the management policy and relevant control program of the valuation model for fair value of The Group, the management team believes it is appropriate and necessary to adjust the evaluation for expressing the fair value of the financial instrument and non-financial instrument in the aggregate balance sheet. The price information and parameter used in the valuation process is evaluated prudently and adjusted according to the current market situation properly.

5. The changes in Level 3 for the three months ended March 31, 2026 and 2025, respectively, are described as follows:

	<u>2026</u>	<u>2025</u>
	Equity instruments	Equity instruments
January 1	\$ 102,704	\$ 98,423
Increase of the current period	16,060	97
Evaluation adjustment	(14,177)	(7,416)
Capital reduction and refund of the equity instruments measured at fair value through other comprehensive income	(7,442)	-
Foreign exchange impact amount	(811)	961
March 31	<u>\$ 96,334</u>	<u>\$ 92,065</u>

6. The valuation process for classifying the fair value to the third level of The Group is proceeded by the financial center for the independent fair value valuation of the financial instrument, by using the independent sources to have the valuation result close to the market status, and make sure that the sources of the information is independent, reliable and consistent with other resources as well as all other necessary adjustment of fair value, to ensure the valuation result is reasonable.

Besides, the valuation policy, valuation process and confirmation for the fair value of the financial instrument set by the Ministry of Finance meet the regulations of relevant international financial reporting standards.

7. The sensitivity analysis explanation of the quantitative data of significant non-observable input value and change of significant non-observable input value which belongs to the valuation model for the items to review the third level of fair value is as follows:

	<u>March 31, 2026</u>			
	<u>Fair value</u>	<u>Valuation technique</u>	<u>Significant unobservable input value</u>	<u>Relationship between input value and fair value</u>
Stock of the venture capital	\$ 96,334	Net assets value method	Not applicable	Not applicable
	<u>December 31, 2025</u>			
	<u>Fair value</u>	<u>Valuation technique</u>	<u>Significant unobservable input value</u>	<u>Relationship between input value and fair value</u>
Stock of the venture capital	\$ 102,704	Net assets value method	Not applicable	Not applicable
	<u>March 31, 2025</u>			
	<u>Fair value</u>	<u>Valuation technique</u>	<u>Significant unobservable input value</u>	<u>Relationship between input value and fair value</u>
Stock of the venture capital	\$ 92,065	Net assets value method	Not applicable	Not applicable

8. The valuation and valuation parameter chosen by The Group is evaluated properly, however, the different valuation model or valuation parameter may lead in different valuation result.

13. Notes of disclosure

(1) Information about important transactions

According to the “Regulations Governing the Preparation of Financial Reports by Securities Issuers.” The significant transaction matters of The Company for the three months ended March 31, 2026 were as follows:

1. The Loaning of funds: please see attached table 1.
2. Endorsement and Guarantee: please see attached table 2.
3. Major securities held at the end of the period (excluding investments in subsidiaries, affiliates, and joint ventures): Please see attached table 3.
4. Purchase/sale amount of transactions with related parties reaching 100 million or more than 20% of the paid-in capital: please see the attached table 4.
5. Amounts receivable from related parties totaling more than 100 million or 20% of paid up capital: please see attached table 5.
6. Business relationships and significant transactions between the parent company and its subsidiaries: Please refer to attached table 6.

(2) Information related to reinvested enterprises

The relevant information of names, area of location of the investees (excluding the investees in China), please see attached table 7.

(3) Information about investment in mainland China

1. Basic information: Please see attached table 8.
2. Significant transactions with investee companies in the Mainland China, either directly or indirectly through a third country: Not applicable.

14. Segment information

(1) General information

The management team of The Company has identified the reportable segments according to the information used in making decision by the board of director.

The board of director of The Group operates and evaluates the segments performance in view of the regional diversity.

(2) Segment information

The information provided for the major operation decision maker for the reportable segments is as follows:

January 1 to March 31, 2026	Taiwan	China	Adjust and eliminate	Total
External revenue	\$ 1,820,206	\$ 408,651	\$ -	\$ 2,228,857
Inter-segment income	649,428	-	(649,428)	-
Revenue of the reportable segments.	<u>\$ 2,469,634</u>	<u>\$ 408,651</u>	<u>(\$ 649,428)</u>	<u>\$ 2,228,857</u>
Pre-tax net income of the segments before being adjusted	\$ 140,440	\$ 45,063	\$ 18,640	\$ 204,143
Investment profit or loss recognized according to the Equity Method	269,134	(2)	(231,444)	37,688
Pre-tax net income of the reportable segments	<u>\$ 409,574</u>	<u>\$ 45,061</u>	<u>(\$ 212,804)</u>	<u>\$ 241,831</u>
Asset of the reportable segments	<u>\$ 10,909,814</u>	<u>\$ 1,673,453</u>		<u>\$ 12,583,267</u>
Profits or losses of the segments include:				
Depreciation and amortization	<u>\$ 75,004</u>	<u>\$ 14,047</u>		<u>\$ 89,051</u>
January 1 to March 31, 2025	Taiwan	China	Adjust and eliminate	Total
External revenue	\$ 1,753,954	\$ 501,674	\$ -	\$ 2,255,628
Inter-segment income	697,917	-	(697,917)	-
Revenue of the reportable segments.	<u>\$ 2,451,871</u>	<u>\$ 501,674</u>	<u>(\$ 697,917)</u>	<u>\$ 2,255,628</u>
Pre-tax net income of the segments before being adjusted	\$ 154,571	(\$ 14,263)	\$ 390	\$ 140,698
Investment profit or loss recognized according to the Equity Method	206,168	(2)	(199,235)	6,931
Pre-tax net income of the reportable segments	<u>\$ 360,739</u>	<u>(\$ 14,265)</u>	<u>(\$ 198,845)</u>	<u>\$ 147,629</u>
Asset of the reportable segments	<u>\$ 11,001,877</u>	<u>\$ 1,594,477</u>		<u>\$ 12,596,354</u>
Profits or losses of the segments include:				
Depreciation and amortization	<u>\$ 74,036</u>	<u>\$ 12,621</u>		<u>\$ 86,657</u>

(3) The adjusted information of the profits or losses of the segments

The pre-tax profit/ loss of the reportable segments is the same as that of the business segments, therefore, no adjustment has to be made.

Cenra Inc. and subsidiaries
The Loaning of Funds
January 1 to March 31, 2026

Attached table 1

Unit: NTD thousand
(Except where otherwise stated)

No. (Note 1)	The lender of fund	The borrower of fund	Transaction title	Are they related parties	Maximum balance – current period (Note 2)	Balance, ending	The actual amounts disbursed	Interest rate collars	Nature of financing (Note 3)	Amount of business transactions	Reasons for the necessity of short-term financing	Amount of provision for bad debts	Collateral		Limit of financing particular beneficiary	Total limit of financing	Remarks
													Name	Value			
1	China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Senior Lifestyle Services Co. Ltd.	Other receivables	Y	\$ 20,000	\$ 20,000	\$ -	2.00%	2	\$ -	Working capital	\$ -		\$ -	\$ 1,087,833	\$ 2,175,665	Note 4 (2)
1	China Chemical & Pharmaceutical Co., Ltd.	HU-YU Co., Ltd.	Other receivables	Y	157,589	150,580	150,580	2.01%	1	151,567	-	22,587		-	151,567	2,175,665	Note 4 (1), (2) and Note 5
2	Tairung Enterprise Co., Ltd.	HU-YU Co., Ltd.	Other receivables	Y	46,000	46,000	46,000	2.30%	2	-	Working capital	-		-	45,813	45,813	Note 4(4), Note 5
3	Chunghwa Yuming Healthcare Co., Ltd.	HU-YU Co., Ltd.	Other receivables	Y	107,000	47,000	47,000	2.10%	2	-	Working capital	12,000		-	117,020	234,040	Note 4(5), Note 5
4	Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd.	Other receivables	Y	50,393	50,393	50,393	-	2	-	Working capital	-		-	193,235	386,470	Note 4 (3)

Note 1: The filing method for the numbering of lending money by the Company is as follows:

- (1) Fill in 0 for the issuer.
- (2) The investees are sequentially numbered from 1 and so forth.

Note 2: Maximum balance of financing a third party in current period.

Note 3: Below are the two filing methods for the nature of lending money

- (1) With business dealings
- (2) With necessity of short-term financing

Note 4: Maximum and aggregate amount of loans made to a single entity by the Company:

- (1) Company and its subsidiaries with business transactions with the company whose individual lending amount may not exceed the most recent one year or the current year's incoming goods amount or total sales amount with the company, at the time of capital lending.
- (2) No loan made to a single entitle by China Chemical & Pharmaceutical Co., Ltd. shall exceed 15% of its net worth. Aggregated loans made shall not exceed 30% of its net worth.
- (3) No loan made to a single entitle by Chunghwa Yuming shall exceed 15% of its net worth. Aggregated loans made shall not exceed 30% of its net worth.
- (4) No loan made to a single entitle by Tairung Enterprise Co., Ltd. shall exceed 40% of its net worth. Aggregated loans made shall not exceed 40% of its net worth.
- (5) No loan made to a single entitle by Chunghwa Yuming Healthcare Co. shall exceed 15% of its net worth. Aggregated loans made shall not exceed 30% of its net worth.

Note 5: The full value guarantee will be provided by the Chairman of The Company

Cenra Inc. and subsidiaries
Endorsements and guarantees made for others
January 1 to March 31, 2026

Attached table 2

Unit: NTD thousand
(Except where otherwise stated)

No. (Note 1)	The company providing the endorsement and/or guarantee	The party receiving the endorsement and/or guarantee		The limit of endorsements and/or guarantees to a single business entity	The highest balance of endorsements and/or guarantees in the current period	The ending balance of endorsements and/or guarantees	The actual amounts disbursed	Amount of property pledged for endorsements /guarantees	Total endorsements and guarantees as a percentage of equity in the most recent financial statement	The upper limit of an endorsement and/or guarantee	Guarantee and endorsement of parent company to subsidiary	Guarantee and endorsement by subsidiary to parent company	Guarantee and endorsement in Mainland China	Remarks
		Company name	Relation (Note 2)											
1	China Chemical & Pharmaceutical Co., Ltd.	HU-YU Co., Ltd.	1	\$ 151,567	\$ 250,600	\$ 223,600	\$ 151,300	\$ -	3.08%	\$3,626,109	N	N	N	Note 3, 4, 5 and 6

Note 1: The column for numbering is elaborated below:

- (1) Fill in 0 for the issuer.
- (2) The investees are sequentially numbered from 1 and so forth.

Note 2: The 6 types of relations between the endorsement/ guarantee provider and subject of endorsement/ guarantee are as follows. Indication of types is applicable.

- (1) Business relation.
- (2) Subsidiary owns over 50% of ordinary equity share with direct possession.
- (3) The aggregation of the ordinary share possessed by The Company and its Subsidiary exceeds 50% by the investee.
- (4) The Parent Company which possesses more than 50% of the ordinary equity share directly or through its Subsidiary with indirect possession.
- (5) For building construction, The Company holds a mutual guarantee with other companies based on the peer agreement.
- (6) Due to the joint investment relationship, shareholders are to provide endorsement and guarantee to the company proportionately to the respective shareholding ratio.

Note 3: Endorsement and guarantee to a particular enterprise shall not exceed 30% of the net worth of the CCPC. The limit of endorsement and guarantee to companies in business transactions with the CCPC shall not exceed the amount of purchase or sale with the CCPC in the previous period or current period at the time of endorsement and guarantee, whichever is higher.

Note 4: The endorsement/ guarantee amount of the CCPC is limited to 50% of the net value of the CCPC.

Note 5: Included in the maximum balance of endorsements and guarantees was \$ 72,300 arising from the renewal contract having been submitted to the Board of Directors for approval prior to the expiration of the original contract. The actual guarantee exposure undertaken by CCPC on behalf of Hu Yu Co., Ltd. was \$ 178,300.

Note 6: Included in the ending balance of endorsements and guarantees was \$ 72,300 arising from the renewal contract having been submitted to the Board of Directors for approval prior to the expiration of the original contract term. The actual guarantee exposure undertaken by CCPC on behalf of Hu Yu Co., Ltd. amounted to \$151,300, representing 2.09% of the net worth reported in the most recent financial statements.

Cenra Inc. and subsidiaries

Major securities held at the end of the period (excluding investments in subsidiaries, associates, and joint ventures)

March 31, 2026

Attached table 3

Unit: NTD thousand
(Except where otherwise stated)

Holding company	Types of negotiable securities	Names of negotiable securities (Note 1)	Relationship with the securities issuer	Account titles in book	At ending				Remarks
					Number of shares	Book value	Ratio of Shareholding	Fair value	
China Holdings Co., Ltd.	Equity	Eterna Capital	-	Investment of equity instruments at fair value through other comprehensive income	-	\$ 16,060	8.77%	\$ 16,060	None
China Chemical & Pharmaceutical Co., Ltd.	Stock	momo.com Inc.	-	"	119,991	21,238	0.05%	21,238	None
	"	Green Management International Co., Ltd.	-	"	111,237	1,759	5.21%	1,759	"
	"	CDIB Capital Healthcare Ventures Limited	-	"	2,434,286	21,034	1.71%	21,034	"
	"	MegaPro Biomedical Co., Ltd.	Other related parties	"	2,938,458	29,003	3.70%	29,003	"
	"	Genovate Biotechnology Co., Ltd.	-	"	1,785,700	58,035	1.30%	58,035	"
	Equity	Seraph partners	-	"	-	8,941	2.96%	8,941	"
Tairung Enterprise Co., Ltd.	Stock	Cenra Inc.	The Company	"	413,941	13,536	0.28%	13,536	None
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Equity	Kunshan CDIB Yida Healthcare Enterprise Ltd.	-	"	-	48,540	2.37%	48,540	None

Note 1: Securities as stated in this table are the stocks, bonds, beneficiary certificates and the securities deriving from the above items within the scope of IFRS 9, "Financial Instruments"

Note 2: The Company determines the securities to be listed in accordance with the principle of materiality and does not disclose the securities with a carrying amount of less than NTD 1,000.

Cenra Inc. and subsidiaries

Purchase from or sale to related parties for an amount exceeding NTD 100 million or 20% of paid-in capital

January 1 to March 31, 2026

Attached table 4

Unit: NTD thousand

Purchase (sale) company	Name of counterparty	Relation	Transactions				Trading terms different from general trade and reasons		Notes and accounts receivable (payable)		Remarks
			Purchase (sale)	Amount	Percentage of total purchase (sale)	The credit period	Unit price	The credit period	Balance	Percentage of total notes and accounts receivable (payable)	
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Yuming Healthcare Co., Ltd.	Subsidiaries	Sale	\$ 648,027	66.03%	The payment term is 150 days	Agreed by the quotation in the purchase agreement signed by both parties.	The payment term is 150 days.	\$ 1,788,290	76.66%	

Note: Individual accounts payable transactions less than NTD 100,000 will not be disclosed.

Cenra Inc. and subsidiaries

Accounts receivable from related parties for an amount exceeding NTD 100 million or 20% of paid-in capital

March 31, 2026

Attached table 5

Unit: NTD thousand

(Except where otherwise stated)

The company booked in the receivables	Name of counterparty	Relation	Receivables from related party	Turnover rate	Overdue Receivables from related parties		Receivables amount collected from related parties subsequently	Amount of provision for bad debts	Remarks
					Amount	Process			
China Chemical & Pharmaceutical Co., Ltd.	HU-YU Co., Ltd.	The Chairman is the same person of The Company.	\$ 318,730	0.22	\$ 150,580	To obtain the proven guarantee from the chairman of The Company and take joint and several liability for the unpaid debts or bills.	\$ -	\$ 47,773	
"	Chunghwa Yuming Healthcare Co., Ltd.	Subsidiaries	1,788,290	1.46	621,547	Active debt collection.	-	-	

Cenra Inc. and subsidiaries

Business relationships and significant transactions between parent company and subsidiaries

January 1 to March 31, 2026

Attached table 6

Unit: NTD thousand
(Except where otherwise stated)

No. (Note 1)	Trader's name	Counterparty	Affiliation to trader (Note 2)	Transactions			Percentage in consolidated total revenue or total assets (Note 3)
				Title	Amount	Terms and conditions	
1	CCPC	Chunghwa Yuming Healthcare Co., Ltd.	3	Sale	\$ 648,027	Note 4	29.07%
1	"	"	3	Accounts receivable	1,788,290	"	14.21%

Note 1: The information about transactions between parent company and subsidiaries shall be numbered and noted in the following manner in the box of numbers:

- (1) Fill in "0" for parent company.
- (2) Subsidiaries are numbered from number 1.

Note 2: There are three types of relationships with traders, please mark the type intended.

- (1) Parent company vs. subsidiaries.
- (2) Subsidiaries vs. parent company.
- (3) Subsidiaries vs. subsidiaries.

Note 3: For computing the ratio of trade amount to total sales revenue or total assets, if it is for asset and liability account, the computation is based on the ratio of ending balance to total consolidated assets; however, if it is for income and expense account, the computation is based on the ratio of interim cumulative amount to total consolidated revenue.

Note 4: The selling price is agreed to by the quotation in the purchase agreement signed by both parties. The payment of the selling goods is 150 days.

Note 5: The significant matters between the parent company and subsidiaries have been written off.

Note 6: The amount of individual deal below NTD 100,000 will not be disclosed.

Cenra Inc. and subsidiaries

The relevant information of names, area of location of the investees (excluding the investees in China)

January 1 to March 31, 2026

Attached table 7 Unit: NTD thousand
(Except where otherwise stated)

Investor	Name of investee	Location	Principal business	Sum of initial investment		Ending shareholding			Current period profit / loss of the investee	Recognized investment income	Remarks
				Current period-end	The end of last year	Number of shares	Ratio	Book value			
Cenra Inc.	China Chemical & Pharmaceutical Co., Ltd.	Taiwan	Manufacture and sales of Western medicine preparations and health-care articles.	\$ 6,747,063	\$ 6,747,063	234,890,949	100.00	\$ 7,149,892	\$ 110,622	\$ 125,432	Subsidiaries
Cenra Inc.	Providence Investments Inc.	Taiwan	General investment businesses	25,000	25,000	2,500,000	100.00	25,062	(15)	-	Subsidiaries
Cenra Inc.	Chunghwa Yuming Healthcare Co., Ltd.	Taiwan	Wholesale of medicine and medical equipment	688,485	688,485	29,590,000	100.00	780,132	65,358	65,358	Subsidiaries
China Chemical & Pharmaceutical Co., Ltd.	Tairung Enterprise Co., Ltd.	Taiwan	Manufacture and sales of glass, plastics made containers	226,920	226,920	4,376	71.64	81,795	(1,976)	-	Sub-subsidiary (Note 1)
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Holding Co., Ltd	Cayman Islands	Professional investment company	910,384	910,384	44,485,000	100.00	1,276,357	43,033	-	Sub-subsidiary (Note 1)
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Senior Lifestyle Services Co. Ltd.	Taiwan	Medicine, wholesale of medicine equipment and home care service	354,400	354,400	5,000,000	100.00	(3,397)	(696)	-	Sub-subsidiary (Note 1)
China Chemical & Pharmaceutical Co., Ltd.	Sino-Japan Chemical Co., Ltd.	Taiwan	Manufacture and selling of the chemical materials	37,474	37,474	318,216	21.99	536,202	89,582	-	Equity method (Note1)
China Chemical & Pharmaceutical Co., Ltd.	Chunghwa Chemical Synthesis & Biotech Co., Ltd.	Taiwan	Manufacture and selling of the chemical materials	563,849	563,849	21,575,064	28.05	922,378	90,601	-	Equity method (Note1)
China Chemical & Pharmaceutical Co., Ltd.	PHERMPEP CO., LTD.	Taiwan	Wholesale of biotechnology services and health products.	54,480	54,480	2,483,250	31.04	6,795	(538)	-	Equity method (Note1)
Chunghwa Yuming Healthcare Co., Ltd.	Chunghwa Biomedical Technology Corp.	Taiwan	Manufacturer of cleaning products	17,680	17,680	1,768,000	75.23	20,236	(60)	-	Sub-subsidiary (Note 1)
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Chung-Hwa Le Huo Jian Kang (HK) Co., Ltd.	Hong Kong	Biotech products sold as an agent	-	-	-	100.00	-	-	-	Sub-subsidiary (Note 1)

Note 1: The Company does not recognize investment profit and loss directly.

Note 2: For the relevant information about the significant deals of the investees; please see attached table 1-6.

Cenra Inc. and subsidiaries
Basic information- Information of the investees in China
January 1 to March 31, 2026

Attached table 8

Unit: NTD thousand
(Except where otherwise stated)

Names of investees in China	Principal business	Paid-in shares Capital	Mode of investments (Note 1)	Accumulated amount of investment remitted from Taiwan at beginning	Amount of investment remitted or recovered in current period		Accumulated amount of investment remitted from Taiwan at ending	Current period profit / loss of the investee	The Company's directly or indirectly invested shareholding	Investment Profit or Loss for Current Period (Note 2)	Book value of investment at ending	The investment income received at the end of the current period	Remarks
					Outward remittance	Recover							
Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.	Manufacture and sales of pharmaceutical medicine and health products.	\$ 755,151	2	\$ 768,672	\$ -	\$ -	\$ 768,672	\$ 43,033	100	\$ 43,033	\$1,249,477	\$ 472,412	Note 1 (2), Note 2(2) B
Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd.	Wholesale and sales of pharmaceutical medicine and medical equipment.	132,149	3	-	-	-	-	2,262	100	2,262	(16,358)	-	Note 2(2) C, Note 3
Shanghai Yuhou Trading Co., Ltd. (formerly known as Pei Fu (Shanghai) Co., Ltd.)	Wholesale and sales of medical equipment.	200,070	3	-	-	-	-	(1,193)	100	(1,193)	5,829	-	Note 2(2) C, Note 4
Suzhou Chung-hwa Le Huo Jian Kang Co., Ltd.	E-commerce sales of health products	87,156	3	-	-	-	-	(307)	100	(307)	22,533	-	Note 2(2) C, Note 5
Wuxi Jirui Medical Technology Co., Ltd.	Production and sales of APIs	23,451	3	-	-	-	-	(7)	34	(2)	1,969	-	Note 2(2) C, Note 6
<u>Company name</u>		<u>Accumulated investment from Taiwan to Mainland China at ending</u>		<u>Amount of investment approved by Investment Commission of MOEA</u>			<u>Investment amount approved by the Investment Commission MOEAIC</u>						
China Chemical & Pharmaceutical Co., Ltd.		\$ 296,260		\$ 769,143			\$ 4,351,330						

Note 1: There are three types of investments labeled by the respective number:

- (1) Direct investment in Mainland China.
- (2) Indirect investment in Mainland China through a third country (please specify the investment company in the third country):
Investment in Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd. through Chunghwa Holding Co., Ltd.
- (3) Other ways.

Note 2: Recognized as gains or losses on investment in current period:

- (1) Please note if the investee is still under preparation and there was no investment gain or loss.
- (2) The basis of recognition of investment income is classified into following three types, which should be marked out.
 - A. Financial statements audited and audited and attested by an international accounting firm that has a cooperative relationship with a certified public accounting firm registered in the Republic of China.
 - B. Financial statements audited by the CPAs who audit the parent company in Taiwan.
 - C. Others.

Note 3: Direct investment with RMB 30,000 thousand by Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd.

Note 4: Up to 100% equity of Shanghai Yuhou Trading Co., Ltd. (formerly known as Pei Fu (Shanghai) Co., Ltd.) was purchased with a fund of RMB 1,797 thousand from Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd. in June 2016. In 2023, a total of RMB 41,278 thousand from Suzhou Chung-hwa Chemical&pharmaceutical Industrial Co., Ltd. was used for direct investment.

Note 5: Direct investment with RMB 20,000 by Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial CO., LTD

Note 6: Acquired 34% shareholding of Wuxi Jirui Medical Technology Co., Ltd. by use of RMB 1,802 thousand capital from The Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd.